US20100286380A1 - Pretreatment method for extraction of nucleic acid from biological samples and kits therefor - Google Patents
Pretreatment method for extraction of nucleic acid from biological samples and kits therefor Download PDFInfo
- Publication number
- US20100286380A1 US20100286380A1 US12/778,501 US77850110A US2010286380A1 US 20100286380 A1 US20100286380 A1 US 20100286380A1 US 77850110 A US77850110 A US 77850110A US 2010286380 A1 US2010286380 A1 US 2010286380A1
- Authority
- US
- United States
- Prior art keywords
- reaction mixture
- nucleic acid
- tubes
- group
- protein denaturant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6806—Preparing nucleic acids for analysis, e.g. for polymerase chain reaction [PCR] assay
Definitions
- the present invention relates to methods of treating biological samples, such as plasma and blood samples, for analysis. More specifically, the invention relates to biological sample processing methods that are compatible with subsequent nucleic acid analysis, such as hybridization, amplification and detection.
- Nucleic acid-based genetic methods for identification of microorganisms have greatly reduced the time and labor involved in clinical diagnosis. Such methods include, for example, nucleic acid hybridization (e.g., Southerns/microarrays and slot blots), nucleotide sequencing, nucleic acid cloning techniques, restriction digestion of nucleic acids and nucleic acid amplification.
- nucleic acid amplification has provided means for rapid, sensitive and specific identification of microorganisms by amplification and detection of specific genes or gene fragments.
- diagnostic methods it is of particular interest to apply these nucleic acid analyses to biological samples such as plasma and whole blood samples.
- nucleic acid-based methods Prior to the availability of nucleic acid-based methods for detection and identification of microorganisms, plasma or blood samples were analyzed for the presence of microorganisms by blood culturing.
- processing of clinical samples for nucleic acid analyses requires different criteria than sample processing for culturing. For example, nucleic acids must be released from the microorganism in a form suitable for the analysis; nucleic acids must be present in a composition with the appropriate components, ionic strength and pH for the biochemical reactions of the analysis; and inhibitors of the reactions such as nucleases, if present in the clinical sample or introduced during sample processing, must be removed or rendered non-inhibitory.
- nucleic acid hybridization One potential biochemical detection method involves the use of nucleic acid hybridization.
- sequence specificity embodied in nucleic acids makes it possible to differentiate virtually any two species by nucleic acid hybridization.
- Standard techniques for detection of specific nucleotide sequences generally employ nucleic acids that have been purified away from cellular proteins and other cellular contaminants.
- the most common method of purification involves lysing the cells with sodium dodecyl sulfate (SDS), digesting with proteinase K (ProK), and removing residual proteins and other molecules by extracting with organic solvents such as phenol, chloroform, and isoamylalcohol.
- SDS sodium dodecyl sulfate
- ProK proteinase K
- organic solvents such as phenol, chloroform, and isoamylalcohol.
- RNA ribonucleic acids
- DNases deoxyribonucleases
- RNases ribonucleases
- the present invention addresses the need for a simple and rapid method to treat biological samples such as plasma and blood for extraction of nucleic acid therefrom.
- the method of the present invention pretreats biological samples for extraction of nucleic acid therefrom by mixing the biological samples with at least one protein denaturant and by stepwise heating the mixture in a temperature range of from about 55° C. to about 85° C. to form a reaction mixture.
- the method of the present invention pretreats the biological samples by mixing the biological samples with at least one protein denaturant in a temperature range from about 55° C. to about 85° C. to form a reaction mixture and by diluting the reaction mixture with an aqueous solution or an aprotic solvent.
- the method of the present invention pretreats biological samples for extraction of nucleic acid therefrom by treating the samples with at least one protein denaturant and at least one aprotic solvent at or above about 4° C. to form a reaction mixture for nucleic acid analysis.
- the method of the present invention pretreats biological samples by treating the samples with at least one protein denaturant and at least one aprotic solvent at or above about 25° C.
- ProK is used as the protein denaturant
- formamide is used as the aprotic solvent
- the treatment is conducted at a temperature in the range of about 55° C. to about 85° C. for about 30 minutes.
- purifying and “purification” also include extracting/extraction and isolating/isolation.
- the present invention is a composition and method of treating biological samples such as, for example, plasma and whole blood samples, for extraction of nucleic acid therefrom.
- the present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution.
- the biological samples used according to the present invention may be any biological material containing nucleic acid such as, for example, clinical, forensic or environmental samples. These samples may contain any viral or cellular material, including prokaryotic and eukaryotic cells, viruses, bacteriophages, mycoplasms, protoplasts and organelles. Such biological materials may comprise all types of mammalian and non-mammalian animal cells, plant cells, algae including blue-green algae, fungi, bacteria, yeast and protozoa.
- Representative examples include blood and blood-derived products such as whole blood, plasma and serum; clinical specimens such as semen, urine, feces, sputa, tissues, cell cultures and cell suspensions, nasopharangeal aspirates and swabs, including endocervical, vaginal, occular, throat and buccal swabs; and other biological samples such as finger nails, skin, hair and cerebrospinal fluid or other body fluid.
- blood and blood-derived products such as whole blood, plasma and serum
- clinical specimens such as semen, urine, feces, sputa, tissues, cell cultures and cell suspensions, nasopharangeal aspirates and swabs, including endocervical, vaginal, occular, throat and buccal swabs
- other biological samples such as finger nails, skin, hair and cerebrospinal fluid or other body fluid.
- the protein denaturant is a reagent that is capable of, by itself or when combined with other protein denaturants and/or aprotic solvents, disrupting the protein membranes or walls of cells, virions, DNase or RNase, causing protein denaturation and organism lysis and releasing nucleic acid in biological samples.
- Protein denaturants are well known in the art, and may be purchased from known vendors or prepared using well-known standard techniques.
- Protein denaturants that are useful in the present invention include proteolytic enzymes, such as ProK, pronase, pepsin, trypsin, chymotrypsin, carboxypeptidase and elastase; anionic, non-ionic and zwitterionic detergents such as SDS, lithium dodecyl sulfate (LDS), polyethylene glycol sorbitan monolaurate (i.e., Tween® 20), polyethylene glycol sorbitan monooleate (i.e., Tween® 80), NP-40, dodecyl trimethyl ammonium bromide (DTAB), cetyl trimethyl ammonium bromide (CTAB), 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), polyethylene glycol tert-octylphenyl ether (i.e., Triton X detergents such as Triton X-20 and Tri
- Proteolytic enzymes are generally preferred as the protein denaturant, and ProK is exemplary of such proteolytic enzymes.
- the usefulness of any protein denaturant in the method of the present invention may be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- the concentration of the protein denaturants can vary depending on other agents and conditions, but is sufficient to disrupt the protein membranes or walls of cells, virions, DNase or RNase, causing protein denaturation and organism lysis and releasing nucleic acid in biological samples in the presence of other protein denaturants and/or aprotic solvents.
- This concentration of protein denaturant can be readily determined by those skilled in the art using routine screening methods that do not require undue experimentation.
- ProK is used as the protein denaturant with at least one aprotic solvent, the desirable concentration of ProK depends on the proteinaceous content of the biological samples. For most biological samples, it is in the range of about 1 to about 100 units per milliliter of biological sample.
- some biological samples may require dilution or concentration prior to the pretreatment in order to make use of ProK in its optimal concentration range, i.e., about 1 to about 100 units per milliliter of biological sample.
- concentration of the base or salt is in the range of about 10 to about 400 mM, more preferably about 80 to about 220 mM, and most preferably about 100 mM.
- concentration of the detergent is in the range of about 0.05% to about 8.0%, more preferably about 0.05% to about 4%, and most preferably about 1%.
- More than one protein denaturant can be utilized for the pretreatment according to the present invention.
- the combinations of the same type or different types of protein denaturants offer additional advantages in the pretreatment of biological samples for the extraction of nucleic acids.
- the concentrations of mixed protein denaturants in the method of the present invention can also be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- one or more aprotic solvents are utilized with the protein denaturant(s).
- the aprotic solvent used in the present invention is capable of dissolving ionic substances because of the permanent or induced dipole, which allows the formation of an ion-dipole force.
- Aprotic solvents do not donate suitable hydrogen atoms to form labile hydrogen bonds with anions. Nucleophilic substitution by the SN2 mechanism with a charged nucleophile is often faster in aprotic solvents.
- the dipolar aprotic solvent is a solvent with a comparatively high relative permittivity (or dielectric constant), e.g., greater than about 15, and a dipole moment.
- aprotic solvents do not ionize to form hydrogen ions, which confers advantages.
- Aprotic solvents useful in the present invention include formamide, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), dimethylacetamide (DMAC), acetronitrile, benzene, toluene, acetone, cyclohexane, n-heptane, sulfur dioxide, hexamethylphosphoramide (HMPA) and other non-aqueous media that can be used to denature and solubilize the target nucleic acid.
- Formamide is a preferred aprotic solvent.
- Such aprotic solvents are well known in the art and may be purchased from known vendors or synthesized using well-known standard techniques. The usefulness of any aprotic solvent in the method of the present invention may be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- the concentration of the aprotic solvent can vary depending on other agents and conditions, but is sufficient to protect a nucleic acid by maintaining the nucleic acid in solution at the required temperature and in the presence of at least one protein denaturant. This concentration can be readily determined by those skilled in the art using routine screening methods that do not require undue experimentation.
- the concentration of formamide is preferably in the range of about 10% to about 80% by volume of the reaction mixture, more preferably about 20% to about 40%, and most preferably about 30%.
- More than one aprotic solvent can be utilized for the pretreatment according to the present invention.
- the combinations of different aprotic solvents offer additional advantages in the pretreatment of biological samples for the extraction of nucleic acid therefrom.
- concentrations of mixed aprotic solvents in the methods of the present invention can also be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- the temperatures at which the methods of the present invention are conducted are generally described as at or above about 4° C., preferably at or above about 25° C. A more preferred range is from about 55° C. to about 95° C. An even more preferred range of temperature is about 65° C. to about 85° C. The most preferred temperature is about 70° C. It is believed that the high temperature contributes to the denaturation of proteins in the method of the present invention.
- stepwise heating is utilized with protein denaturant(s) alone or in combination with aprotic solvent(s) for extraction of nucleic acid from biological samples.
- Stepwise heating is a heating procedure that increases or decreases the treatment temperature systematically by two or more steps for the extraction of nucleic acid from biological samples. For example, twenty-minute treatments at each treatment temperature of 55° C. and 85° C. are utilized for the protein denaturation and nucleic acid extraction with the proteolytic enzyme, Pro K. Stepwise heating has shown improved recoveries for nucleic acid extraction.
- the temperature ranges and the duration of the heating steps in the method of the present invention can be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- sample dilution with an aqueous solution or an aprotic solvent is utilized with protein denaturant(s) alone or with aprotic solvent(s).
- the aqueous solution can be water or any buffer solution with a pH value between about 3.0 to about 10.0.
- the sample dilution has shown improved recoveries for nucleic acid extraction.
- the dilution step brings about further protein denaturation and/or precipitation while maintaining the nucleic acid in solution.
- the dilution factor (reaction mixture/diluent) is usually between 4:1 and 1:10 depending on the sample, the diluent and the treatment condition.
- the choice of diluent and dilution factor for use in the method of the present invention can be readily determined by one skilled in the art using routine screening methods that do not require undue experimentation.
- kits for treating a biological sample for the extraction of nucleic acid therefrom comprising at least one protein denaturant with or without one or more aprotic solvents as described herein.
- the kits may contain water and buffer solutions as described herein, as well as iron oxide or other solid supports for nucleic acid purification, which are described in more detail elsewhere.
- the kits may also contain one or more of the following items for processing and assaying the biological samples: collection devices such as swabs, tubes and pipettes; controls; pH indicators; and thermometers.
- Kits may include containers of reagents mixed together in suitable proportions for performing the method in accordance with the present invention.
- Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject method.
- the present invention also includes the reaction mixtures, as well as methods of extracting nucleic acid from the reaction mixtures.
- the reaction mixtures comprise at least one protein denaturant and with or without one or more aprotic solvents.
- the reaction mixtures may in some embodiments include various reagents used with the subject reaction mixtures to purify and detect nucleic acids, such as buffers and iron oxide or other solid supports for nucleic acid purification.
- the reversible binding of nucleic acid molecules on paramagnetic particles in an acidic environment is used for nucleic acid isolation from the reaction mixture resulting from treating samples for extraction of intact nucleic acid according to the present invention.
- the binding pH is preferably about 1 to about 6.5, more preferably about 1 to about 4, and most preferably about 2.
- the elution pH is preferably about 6.5 to about 12, more preferably about 7.5 to about 11, and most preferably about 8.
- the paramagnetic iron oxide technology captures nucleic acids non-specifically, or independent of sequence.
- the most notable non-specific capture systems include the Roche MagNA Pure LC and the Organon Teknika Nuclisens, both of which utilize magnetic silica particles.
- the Qiagen BioRobot 9604 incorporates silica membranes.
- the Roche AmpliPrep captures targets specifically with streptavidin-coated magnetic particles and biotinylated capture probes. GenProbe's Tigris system is expected to utilize oligonucleotide-coated magnetic particles.
- any conventional effective technique for nucleic acid isolation and purification known in the art including liquid and solid phase separation, can be utilized for the isolation and purification of nucleic acids following the pretreatment process of the present invention or, alternatively, the pretreatment process may be performed in the presence or absence of conventional effective techniques for nucleic acid isolation and purification that are known in the art.
- Strand displacement amplification is also utilized in these examples for amplification and detection of the target nucleic acid sequence following the extraction process of the invention and any appropriate isolation or purification step.
- the SDA method involves first mixing single-stranded target sequences with a nucleic acid polymerase, restriction endonuclease, deoxynucleoside triphosphates and at least one primer, which is complementary to a region at the 3′ end of a target fragment, wherein each primer has a sequence at the 5′ end that is a recognition sequence for a restriction endonuclease, and then allowing the mixture to react for a time sufficient to generate reaction products.
- nucleic acids comprise RNA
- reverse transcriptase it is preferable to use reverse transcriptase to convert RNA to cDNA.
- the invention is not limited to SDA detection, and many conventional and effective detection techniques such as hybridization and polymerase chain reaction (PCR) may be used for detection following the pretreatment process of the invention.
- the experiment was designed to evaluate the effect of temperature during the ProK plasma pretreatment of the present invention on extraction of RNA.
- the RNA was extracted from the sample using iron oxide.
- the samples were eluted from the iron oxide in each tube by adding 0.4 mL of elution buffer composed of 45 mM KOH, 90 mM Bicine, and 20 mM KPO 4 and mixing the tubes. Following elution, the eluents were transferred to new tubes by magnetically locking the iron oxide particles to the side and aspirating the sample into new tubes. Next, 1 ug of yeast carrier RNA was added to each tube. The eluted samples were then assayed by SDA using an HIV reverse transcriptase (RT)-SDA assay system. The results were as follows:
- Plasma (uL) Temperature Mean Signal 0 25° C. 95,969 600 25° C. 41,410 600 37° C. 5,896 600 52° C. 46,709
- RNA target recoveries when plasma is pretreated with ProK at temperatures as high as 52° C.
- the following experiment examined the effect of varying ProK concentrations and high temperature plasma pretreatment on extraction of RNA.
- the samples were extracted using iron oxide.
- EDTA anti-coagulated plasma 600 uL collected in PPTTM tubes from Becton Dickinson (BD) was transferred to new tubes, each containing 40-45 mg iron oxide. Following transfer, 220 uL of 30 mM KPB was added to each of the tubes. Next, 3, 6, or 9 units of ProK was added to the tubes, and the tubes were then incubated for 20 minutes in a 55° C., 65° C., or 75° C. water bath. Following incubation, 180 uL of 6 M glycine/HCl was added to each tube, and the tubes were mixed by aspirating up and down with a pipette. Yeast carrier RNA (10 uL of 10 ug/mL) was added to each tube.
- the samples were then spiked with 6 uL of 10 7 copies/mL HIV RNA in vitro transcript.
- the samples were mixed by aspirating and dispensing 800 uL at a time, repeated 24 times.
- the samples were then extracted as described in Example 1, i.e., by magnetically locking the iron oxide particles to the sides of the tubes and aspirating the unbound samples.
- the particles were washed twice with 1 mL of 86 mM glycine/HCl by aspirating and dispensing 800 uL for a total of 12 times, locking the iron oxide particles to the side of the tubes, and aspirating the fluid from tubes.
- the sample was then eluted from the iron oxide by adding 0.4 mL of elution buffer composed of 90 mM Bicine, 50 mM KOH, and 20 mM KPO 4 to each tube, mixing by aspirating and dispensing 300 uL 12 times. Following elution, 10 microliters of yeast carrier RNA (10 mg/mL) was added to each tube. The tubes were then heated to 60° C. while being subjected to magnetic mixing for 20 minutes by alternately turning electromagnets, positioned on opposite sides of the tubes, on and off. This mixed the samples by drawing the iron oxide particles back and forth through the solution.
- elution buffer composed of 90 mM Bicine, 50 mM KOH, and 20 mM KPO 4
- the eluted samples were transferred to new tubes as described in Example 1, i.e., by magnetically locking the iron oxide particle to the side and aspirating the sample into new tubes and, assayed by SDA using an HIV reverse transcriptase (RT)-SDA assay system.
- RT HIV reverse transcriptase
- the following experiment examined the effect of ProK and formamide and varying thermal profiles during plasma pretreatment on extraction of RNA.
- the RNA was extracted from the sample using iron oxide.
- EDTA anti-coagulated plasma 500 uL was added to 64 tubes, each containing 40-45 mg of iron oxide. Eight of these tubes were set aside as controls, i.e. were not pretreated. Phosphate buffered saline (PBS) (300 uL) was added to eight of the tubes. The remaining forty-eight tubes received 300 uL of formamide. To each of the fifty-six tubes that contained either PBS or formamide, 20 units of ProK was added. The tubes were incubated at the temperatures and times specified in the summary table. All of the tubes were then spiked with 2,500 copies of HIV in vitro transcript to simulate a plasma sample containing 5,000 copies/mL HIV RNA.
- PBS Phosphate buffered saline
- the samples were eluted from the particles with the addition of 120 uL of elution buffer composed of 75 mM Bicine, 85 mM KOH and mixing by aspirating and dispensing 100 uL at a time for a total of 15 times.
- the samples were then neutralized by adding 60 uL of neutralization buffer composed of 400 mM Bicine to each tube and mixed by aspirating and dispensing 100 uL at a time for a total of 15 times.
- the eluted samples were transferred to new tubes as described in Example 1.
- the eluted samples were assayed by SDA using an HIV RT-SDA assay system. The results are as follows:
- Human plasma 500 uL was added to each of twelve 2 mL tubes—six containing 40 mg iron oxide and six empty tubes.
- ProK 5 units was added to each tube, and the tubes were incubated for 20 minutes at 65° C.
- Formamide 400 uL was added, and the tubes were incubated for 10 minutes at 70° C.
- the samples that were pretreated without iron oxide were transferred to six new 2 mL tubes containing 40 mg iron oxide.
- 2,500 copies of K10 DNA plasmid containing an M. tuberculosis (TB) specific sequence were spiked into five of the six tubes that were pretreated without iron oxide present and into five of the six tubes that were pretreated with iron oxide present.
- the following experiment was conducted to compare DNA extraction efficiency from plasma when iron oxide is present during plasma pretreatment versus when iron oxide was added after pretreatment and to examine the two conditions with and without an alternating current (AC) field during mixing.
- AC alternating current
- Human plasma 500 uL was added to each of twenty-four 2 mL tubes containing 40 mg iron oxide and to twenty-four empty 2 mL tubes.
- ProK 5 units
- 300 uL formamide were added to each tube. All tubes were incubated for 20 minutes at 65° C. and then for 10 minutes at 85° C. The samples that were pretreated without iron oxide were transferred to new 2 mL tubes containing 40 mg iron oxide.
- 4,000 copies of K10 DNA plasmid containing an M. tuberculosis (TB) specific sequence was spiked into 20 of the 24 tubes that were pretreated without iron oxide present and into 20 of the 24 tubes that were pretreated with iron oxide present.
- Pretreatment AC at Mean DTB Mean IC Cond. Mixing Target Signal Signal No iron oxide None 0 K10/sample 0 45599 4000 K10/sample 41428 40049 30 mV 0 K10/sample 4 37409 4000 K10/sample 69126 33033 40 mg iron oxide None 0 K10/sample 0 51567 4000 K10/sample 10470 44495 30 mV 0 K10/sample 0 32879 4000 K10/sample 7820 36261
- Human plasma 500 uL was added to each of twenty-four 2 mL tubes.
- ProK (5 units) and 400 uL of 30 mM potassium phosphate buffer were added to eight of the plasma tubes and incubated for 20 minutes at 65° C. followed by incubation for 10 minutes at 70° C.
- ProK (9 units) and 400 uL of 30 mM potassium phosphate buffer were added to eight of the plasma tubes and incubated for 20 minutes at 65° C. followed by incubation for 10 minutes at 70° C.
- ProK (5 units) was added to eight of the plasma tubes and incubated for 20 minutes at 65° C. Following the 65° C. incubation, these tubes were diluted with 400 uL of water and incubated for 10 minutes at 70° C.
- Potassium phosphate buffer (900 uL) was added to the remaining eight 2 mL tubes. Each of the solutions were transferred to new 2 mL tubes containing 40 mg iron oxide each.
- 3,000 copies of K10 DNA plasmid containing an M. tuberculosis specific sequence was spiked into six of the eight tubes of each of the four conditions. The remaining two tubes of each condition were left as negative controls.
- 180 uL of 6 M glycine/HCl was added to each tube and mixed by aspirating up and down. The iron oxide particles were magnetically locked to the sides of the tubes, and the unbound samples were aspirated.
- Human plasma was spiked with 10,000 HIV particles per mL, and 500 uL of HIV-spiked plasma was added to forty 2 mL tubes.
- ProK 40 units was added to each tube.
- 300 uL of 30 mM KP containing 0, 2.5, 5, 10, or 20 ug carrier RNA was added to the tubes (eight tubes per carrier RNA level). Given a 0.5 mL plasma sample, this translates into carrier RNA concentrations of 0, 5, 10, 20, and 40 ug per mL plasma.
- 500 uL non-spiked plasma, 40 units of ProK, 300 uL of formamide and 10,000 copies of HIV in vitro transcript were added to eight 2 mL tubes. All tubes were incubated for 30 minutes in a 70° C.
- Neutralization buffer 60 uL
- 400 mM Bicine was added to each tube and mixed by aspirating and dispensing 100 uL 15 times.
- the iron oxide particles were magnetically locked to the sides of the tubes to allow for removal of eluted sample.
- the eluted samples were amplified in a HIV RT-SDA assay. The results are as follows:
- a volume of 600 uL plasma from BD PPTTM tubes was added to tubes containing 40-45 mg iron oxide, and then 220 uL of 30 mM KPO 4 was added to each of the tubes.
- ProK (6 units) was also added to each tube, and the ProK was activated by incubating the tubes for 20 minutes either in a 55° C. water bath or in a 65° C. water bath. The tubes were transferred to a 75° C. water bath and incubated for 20 minutes. The samples were cooled at room temperature for 5 minutes. Next, 180 uL of 6 M glycine/HCl was added to each tube, and the samples were pipette mixed.
- yeast carrier RNA 10 ug/mL was added to each tube, followed by 6 uL HIV stock RNA (10 7 copies/ml) and pipette mixed.
- the unbound samples were removed from the tubes by locking iron oxide particles to the side of tube and aspirating the solution to waste.
- the particles were washed three times with 1000 uL wash solution (86 mM glycine/HCl) by pipette mixing, locking iron oxide particles to the side of each tube, and aspirating unbound solution.
- elution buffer 90 mM Bicine, 50 mM KOH and 20 mM KPO 4 .
- Yeast carrier RNA (10 ug) was added to each tube.
- the target was added to pre-assay spiked control samples.
- the samples were removed to new tubes as described in Example 1 and assayed by an HIV RT-SDA assay. The results are as follows:
- This experiment was conducted to extract RNA from whole blood and examine the use of additional wash steps to decrease carryover of inhibitory components into the elution step.
Abstract
The present invention relates to methods for pretreating biological samples for extraction of nucleic acid therefrom. The present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution.
Description
- This application is a divisional of U.S. application Ser. No. 12/359,854, filed Jan. 26, 2009, which is a continuation of U.S. application Ser. No. 10/359,179, filed Feb. 6, 2003, now, U.S. Pat. No. 7,601,491, the disclosures of which are hereby incorporated herein by reference.
- The present invention relates to methods of treating biological samples, such as plasma and blood samples, for analysis. More specifically, the invention relates to biological sample processing methods that are compatible with subsequent nucleic acid analysis, such as hybridization, amplification and detection.
- Nucleic acid-based genetic methods for identification of microorganisms have greatly reduced the time and labor involved in clinical diagnosis. Such methods include, for example, nucleic acid hybridization (e.g., Southerns/microarrays and slot blots), nucleotide sequencing, nucleic acid cloning techniques, restriction digestion of nucleic acids and nucleic acid amplification. In particular, nucleic acid amplification has provided means for rapid, sensitive and specific identification of microorganisms by amplification and detection of specific genes or gene fragments. For use as diagnostic methods, it is of particular interest to apply these nucleic acid analyses to biological samples such as plasma and whole blood samples. Prior to the availability of nucleic acid-based methods for detection and identification of microorganisms, plasma or blood samples were analyzed for the presence of microorganisms by blood culturing. However, processing of clinical samples for nucleic acid analyses requires different criteria than sample processing for culturing. For example, nucleic acids must be released from the microorganism in a form suitable for the analysis; nucleic acids must be present in a composition with the appropriate components, ionic strength and pH for the biochemical reactions of the analysis; and inhibitors of the reactions such as nucleases, if present in the clinical sample or introduced during sample processing, must be removed or rendered non-inhibitory.
- One potential biochemical detection method involves the use of nucleic acid hybridization. The sequence specificity embodied in nucleic acids makes it possible to differentiate virtually any two species by nucleic acid hybridization. Standard techniques for detection of specific nucleotide sequences generally employ nucleic acids that have been purified away from cellular proteins and other cellular contaminants. The most common method of purification involves lysing the cells with sodium dodecyl sulfate (SDS), digesting with proteinase K (ProK), and removing residual proteins and other molecules by extracting with organic solvents such as phenol, chloroform, and isoamylalcohol.
- Endogenous nucleases released during cell solubilization can frustrate efforts to recover intact nucleic acids, particularly ribonucleic acids (RNA). While deoxyribonucleases (DNases) are easily inactivated by the addition of chelating agents to the lysis solution, ribonucleases (RNases) are far more difficult to eliminate. RNases are ubiquitous, being present even in the oil found on human hands. Accordingly, protecting against RNase is a commonly acknowledged aspect of any standard RNA preparation technique. The standard procedure for preparing laboratory stocks of pancreatic RNase is to boil a solution of the enzyme for 15 minutes. The purpose of this treatment is to destroy all traces of contaminating enzyme activity because other enzymes cannot survive boiling.
- Sambrook, et al., Molecular Cloning, 3rd Edition (2001), a compendium of commonly followed laboratory practices, recommends extensive precautions to avoid RNase contamination in laboratories. Such precautions include preparing all solutions that will contact RNA using RNase-free glassware, autoclaved water, and chemicals reserved for work with RNA that are dispensed exclusively with baked spatulas. Besides purging laboratory reagents of RNase, RNase inhibitors are typically included in lysis solutions. These are intended to destroy endogenous RNases that generally become activated during cell lysis. Also, it is common practice to solubilize RNA in diethyl pyrocarbonate (DEPC)-treated water. Moreover, in an attempt to improve the handling of RNA samples, formamide has been tested as a solubilizing agent for the long-term storage of RNA. Chomczynski, P., Nucleic Acids Research 20, 3791-3792 (1992).
- Protecting against RNase is cumbersome and costly, and typical extraction procedures require the handling of caustic solvents, access to water baths, fume hoods, and centrifuges, and even the storage and disposal of hazardous wastes. The direct analysis of unfractionated solubilized biological samples would avoid the cost and inconvenience of these purification techniques.
- In view of the foregoing, there exists a need for a simple and rapid method by which biological samples such as plasma and blood may be treated for the extraction therefrom of nucleic acid for analysis.
- The present invention addresses the need for a simple and rapid method to treat biological samples such as plasma and blood for extraction of nucleic acid therefrom. In one embodiment, the method of the present invention pretreats biological samples for extraction of nucleic acid therefrom by mixing the biological samples with at least one protein denaturant and by stepwise heating the mixture in a temperature range of from about 55° C. to about 85° C. to form a reaction mixture. In another embodiment, the method of the present invention pretreats the biological samples by mixing the biological samples with at least one protein denaturant in a temperature range from about 55° C. to about 85° C. to form a reaction mixture and by diluting the reaction mixture with an aqueous solution or an aprotic solvent. Yet in another embodiment, the method of the present invention pretreats biological samples for extraction of nucleic acid therefrom by treating the samples with at least one protein denaturant and at least one aprotic solvent at or above about 4° C. to form a reaction mixture for nucleic acid analysis. In a preferred embodiment, the method of the present invention pretreats biological samples by treating the samples with at least one protein denaturant and at least one aprotic solvent at or above about 25° C. In an exemplary embodiment of the present invention, ProK is used as the protein denaturant, formamide is used as the aprotic solvent, and the treatment is conducted at a temperature in the range of about 55° C. to about 85° C. for about 30 minutes.
- As used herein, the terms “purifying” and “purification” also include extracting/extraction and isolating/isolation.
- The present invention is a composition and method of treating biological samples such as, for example, plasma and whole blood samples, for extraction of nucleic acid therefrom. The present invention employs a combination of at least one protein denaturant with one or more of the following elements to form a reaction mixture for extraction of nucleic acid: (1) at least one aprotic solvent, (2) stepwise heating, and (3) sample dilution.
- The biological samples used according to the present invention may be any biological material containing nucleic acid such as, for example, clinical, forensic or environmental samples. These samples may contain any viral or cellular material, including prokaryotic and eukaryotic cells, viruses, bacteriophages, mycoplasms, protoplasts and organelles. Such biological materials may comprise all types of mammalian and non-mammalian animal cells, plant cells, algae including blue-green algae, fungi, bacteria, yeast and protozoa. Representative examples include blood and blood-derived products such as whole blood, plasma and serum; clinical specimens such as semen, urine, feces, sputa, tissues, cell cultures and cell suspensions, nasopharangeal aspirates and swabs, including endocervical, vaginal, occular, throat and buccal swabs; and other biological samples such as finger nails, skin, hair and cerebrospinal fluid or other body fluid.
- The protein denaturant is a reagent that is capable of, by itself or when combined with other protein denaturants and/or aprotic solvents, disrupting the protein membranes or walls of cells, virions, DNase or RNase, causing protein denaturation and organism lysis and releasing nucleic acid in biological samples. Protein denaturants are well known in the art, and may be purchased from known vendors or prepared using well-known standard techniques. Protein denaturants that are useful in the present invention include proteolytic enzymes, such as ProK, pronase, pepsin, trypsin, chymotrypsin, carboxypeptidase and elastase; anionic, non-ionic and zwitterionic detergents such as SDS, lithium dodecyl sulfate (LDS), polyethylene glycol sorbitan monolaurate (i.e., Tween® 20), polyethylene glycol sorbitan monooleate (i.e., Tween® 80), NP-40, dodecyl trimethyl ammonium bromide (DTAB), cetyl trimethyl ammonium bromide (CTAB), 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate (CHAPS), polyethylene glycol tert-octylphenyl ether (i.e., Triton X detergents such as Triton X-20 and Triton X-100); surfactants such as surfactin; solvents such as phenol, chloroform, and isoamylalcohol; amides such as N-ethylacetamide, N-butylacetamide and N,N-dimethyl-acetamide; reducing agents such as glutathione, β-mercaptoethanol and dithiothereitol (DTT); protein denaturing salts such as NaCl, KCl, LiCl, NH4Cl, (NH4)2SO4 and perchlorate salt; and agents that cause an increase in pH such as KOH, NaOH, NH4OH and Ca(OH)2. Proteolytic enzymes are generally preferred as the protein denaturant, and ProK is exemplary of such proteolytic enzymes. The usefulness of any protein denaturant in the method of the present invention may be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- When used in the methods of the present invention, the concentration of the protein denaturants can vary depending on other agents and conditions, but is sufficient to disrupt the protein membranes or walls of cells, virions, DNase or RNase, causing protein denaturation and organism lysis and releasing nucleic acid in biological samples in the presence of other protein denaturants and/or aprotic solvents. This concentration of protein denaturant can be readily determined by those skilled in the art using routine screening methods that do not require undue experimentation. When ProK is used as the protein denaturant with at least one aprotic solvent, the desirable concentration of ProK depends on the proteinaceous content of the biological samples. For most biological samples, it is in the range of about 1 to about 100 units per milliliter of biological sample. However, some biological samples may require dilution or concentration prior to the pretreatment in order to make use of ProK in its optimal concentration range, i.e., about 1 to about 100 units per milliliter of biological sample. When a base or a salt is used as the protein denaturant, for most biological samples, the concentration of the base or salt is in the range of about 10 to about 400 mM, more preferably about 80 to about 220 mM, and most preferably about 100 mM. When a detergent is used as the protein denaturant, for most biological samples, the concentration of the detergent is in the range of about 0.05% to about 8.0%, more preferably about 0.05% to about 4%, and most preferably about 1%.
- More than one protein denaturant can be utilized for the pretreatment according to the present invention. The combinations of the same type or different types of protein denaturants offer additional advantages in the pretreatment of biological samples for the extraction of nucleic acids. The concentrations of mixed protein denaturants in the method of the present invention can also be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- In one embodiment, one or more aprotic solvents are utilized with the protein denaturant(s). The aprotic solvent used in the present invention is capable of dissolving ionic substances because of the permanent or induced dipole, which allows the formation of an ion-dipole force. Aprotic solvents do not donate suitable hydrogen atoms to form labile hydrogen bonds with anions. Nucleophilic substitution by the SN2 mechanism with a charged nucleophile is often faster in aprotic solvents.
- The dipolar aprotic solvent is a solvent with a comparatively high relative permittivity (or dielectric constant), e.g., greater than about 15, and a dipole moment. However, unlike water, the more common polar solvent, aprotic solvents do not ionize to form hydrogen ions, which confers advantages.
- Aprotic solvents useful in the present invention include formamide, dimethylformamide (DMF), dimethyl sulfoxide (DMSO), dimethylacetamide (DMAC), acetronitrile, benzene, toluene, acetone, cyclohexane, n-heptane, sulfur dioxide, hexamethylphosphoramide (HMPA) and other non-aqueous media that can be used to denature and solubilize the target nucleic acid. Formamide is a preferred aprotic solvent. Such aprotic solvents are well known in the art and may be purchased from known vendors or synthesized using well-known standard techniques. The usefulness of any aprotic solvent in the method of the present invention may be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- When used in the method of the present invention, the concentration of the aprotic solvent can vary depending on other agents and conditions, but is sufficient to protect a nucleic acid by maintaining the nucleic acid in solution at the required temperature and in the presence of at least one protein denaturant. This concentration can be readily determined by those skilled in the art using routine screening methods that do not require undue experimentation. When formamide is the aprotic solvent used in the method of the present invention, for most biological samples, the concentration of formamide is preferably in the range of about 10% to about 80% by volume of the reaction mixture, more preferably about 20% to about 40%, and most preferably about 30%.
- More than one aprotic solvent can be utilized for the pretreatment according to the present invention. The combinations of different aprotic solvents offer additional advantages in the pretreatment of biological samples for the extraction of nucleic acid therefrom. The concentrations of mixed aprotic solvents in the methods of the present invention can also be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- The temperatures at which the methods of the present invention are conducted are generally described as at or above about 4° C., preferably at or above about 25° C. A more preferred range is from about 55° C. to about 95° C. An even more preferred range of temperature is about 65° C. to about 85° C. The most preferred temperature is about 70° C. It is believed that the high temperature contributes to the denaturation of proteins in the method of the present invention.
- In another embodiment of the invention, stepwise heating is utilized with protein denaturant(s) alone or in combination with aprotic solvent(s) for extraction of nucleic acid from biological samples. Stepwise heating is a heating procedure that increases or decreases the treatment temperature systematically by two or more steps for the extraction of nucleic acid from biological samples. For example, twenty-minute treatments at each treatment temperature of 55° C. and 85° C. are utilized for the protein denaturation and nucleic acid extraction with the proteolytic enzyme, Pro K. Stepwise heating has shown improved recoveries for nucleic acid extraction. The temperature ranges and the duration of the heating steps in the method of the present invention can be readily ascertained by one skilled in the art using routine screening methods that do not require undue experimentation.
- In yet another embodiment of the present invention, sample dilution with an aqueous solution or an aprotic solvent is utilized with protein denaturant(s) alone or with aprotic solvent(s). The aqueous solution can be water or any buffer solution with a pH value between about 3.0 to about 10.0. The sample dilution has shown improved recoveries for nucleic acid extraction. The dilution step brings about further protein denaturation and/or precipitation while maintaining the nucleic acid in solution. The dilution factor (reaction mixture/diluent) is usually between 4:1 and 1:10 depending on the sample, the diluent and the treatment condition. The choice of diluent and dilution factor for use in the method of the present invention can be readily determined by one skilled in the art using routine screening methods that do not require undue experimentation.
- Yet another aspect of the present invention is to provide kits for treating a biological sample for the extraction of nucleic acid therefrom, wherein the kits comprise at least one protein denaturant with or without one or more aprotic solvents as described herein. The kits may contain water and buffer solutions as described herein, as well as iron oxide or other solid supports for nucleic acid purification, which are described in more detail elsewhere. The kits may also contain one or more of the following items for processing and assaying the biological samples: collection devices such as swabs, tubes and pipettes; controls; pH indicators; and thermometers. Kits may include containers of reagents mixed together in suitable proportions for performing the method in accordance with the present invention. Reagent containers preferably contain reagents in unit quantities that obviate measuring steps when performing the subject method.
- The present invention also includes the reaction mixtures, as well as methods of extracting nucleic acid from the reaction mixtures. The reaction mixtures comprise at least one protein denaturant and with or without one or more aprotic solvents. The reaction mixtures may in some embodiments include various reagents used with the subject reaction mixtures to purify and detect nucleic acids, such as buffers and iron oxide or other solid supports for nucleic acid purification.
- The invention will now be described in greater detail by way of the specific examples. The following examples are offered for illustrative purposes and are not intended to limit the invention in any manner. In these examples, the reversible binding of nucleic acid molecules on paramagnetic particles in an acidic environment, as disclosed in U.S. Pat. No. 5,973,138 to Collis, which is incorporated herein by reference, is used for nucleic acid isolation from the reaction mixture resulting from treating samples for extraction of intact nucleic acid according to the present invention. The binding pH is preferably about 1 to about 6.5, more preferably about 1 to about 4, and most preferably about 2. The elution pH is preferably about 6.5 to about 12, more preferably about 7.5 to about 11, and most preferably about 8. The paramagnetic iron oxide technology captures nucleic acids non-specifically, or independent of sequence. There are several other automated nucleic acid extraction technologies currently on the market, representing both specific and non-specific capture. The most notable non-specific capture systems include the Roche MagNA Pure LC and the Organon Teknika Nuclisens, both of which utilize magnetic silica particles. The Qiagen BioRobot 9604 incorporates silica membranes. The Roche AmpliPrep captures targets specifically with streptavidin-coated magnetic particles and biotinylated capture probes. GenProbe's Tigris system is expected to utilize oligonucleotide-coated magnetic particles. In addition, materials such as iron oxide, silica-coated particles, silica-coated membranes, glass fiber mats, glass membranes and other glasses, zeolites and ceramics can also be used as a solid phase binding surface for nucleic acid extraction. In summary, any conventional effective technique for nucleic acid isolation and purification known in the art, including liquid and solid phase separation, can be utilized for the isolation and purification of nucleic acids following the pretreatment process of the present invention or, alternatively, the pretreatment process may be performed in the presence or absence of conventional effective techniques for nucleic acid isolation and purification that are known in the art.
- Strand displacement amplification (SDA) is also utilized in these examples for amplification and detection of the target nucleic acid sequence following the extraction process of the invention and any appropriate isolation or purification step. The SDA method involves first mixing single-stranded target sequences with a nucleic acid polymerase, restriction endonuclease, deoxynucleoside triphosphates and at least one primer, which is complementary to a region at the 3′ end of a target fragment, wherein each primer has a sequence at the 5′ end that is a recognition sequence for a restriction endonuclease, and then allowing the mixture to react for a time sufficient to generate reaction products. Where the nucleic acids comprise RNA, it is preferable to use reverse transcriptase to convert RNA to cDNA. The invention, however, is not limited to SDA detection, and many conventional and effective detection techniques such as hybridization and polymerase chain reaction (PCR) may be used for detection following the pretreatment process of the invention.
- The following examples illustrate the effectiveness of the pretreatment process of the present invention to pretreat whole blood and plasma samples for nucleic acid extraction. Whole blood and plasma are among the most challenging samples for nucleic acid extraction because of their highly proteinaceous content; therefore, the methods of the present invention are expected to be effective for other biological samples as well. Representative examples are discussed herein.
- The experiment was designed to evaluate the effect of temperature during the ProK plasma pretreatment of the present invention on extraction of RNA. The RNA was extracted from the sample using iron oxide.
- First, 40 mg of iron oxide and 1200 uL of 30 mM potassium phosphate buffer (KPB) were dispensed into eight 2 mL polypropylene tubes. Plasma (600 uL), anti-coagulated with EDTA was added to six of the tubes, and 600 uL of 30 mM KPB was added to the remaining two tubes. Three units of ProK were then added to each tube, and the tubes were mixed. The two tubes containing KPB and two of the tubes containing plasma were incubated at room temperature for 20 minutes. Two tubes containing plasma were incubated at 37° C. for 20 minutes, and two tubes containing plasma were incubated at 52° C. for 20 minutes. Following incubation, 180 uL of 6 M glycine/HCl, 1 ug of carrier RNA and 5000 HIV in vitro transcripts were added to each tube. The tubes were then mixed for 15 minutes by alternately turning electromagnets, positioned on opposite sides of the tubes, on and off. This mixed the samples by drawing the iron oxide particles back and forth through the solution. The iron oxide particles were then magnetically locked to the sides of the tubes by turning on the electromagnets. The unbound sample from each tube was then removed by aspiration. The particles were then washed twice with 2 mL of 90 mM glycine/HCl. The tubes were then mixed, the particles were locked to the side, and the fluid removed by aspiration as described above. The samples were eluted from the iron oxide in each tube by adding 0.4 mL of elution buffer composed of 45 mM KOH, 90 mM Bicine, and 20 mM KPO4 and mixing the tubes. Following elution, the eluents were transferred to new tubes by magnetically locking the iron oxide particles to the side and aspirating the sample into new tubes. Next, 1 ug of yeast carrier RNA was added to each tube. The eluted samples were then assayed by SDA using an HIV reverse transcriptase (RT)-SDA assay system. The results were as follows:
-
Plasma (uL) Temperature Mean Signal 0 25° C. 95,969 600 25° C. 41,410 600 37° C. 5,896 600 52° C. 46,709 - The signal responses at various temperatures indicate RNA target recoveries when plasma is pretreated with ProK at temperatures as high as 52° C.
- The following experiment examined the effect of varying ProK concentrations and high temperature plasma pretreatment on extraction of RNA. The samples were extracted using iron oxide.
- EDTA anti-coagulated plasma (600 uL) collected in PPT™ tubes from Becton Dickinson (BD) was transferred to new tubes, each containing 40-45 mg iron oxide. Following transfer, 220 uL of 30 mM KPB was added to each of the tubes. Next, 3, 6, or 9 units of ProK was added to the tubes, and the tubes were then incubated for 20 minutes in a 55° C., 65° C., or 75° C. water bath. Following incubation, 180 uL of 6 M glycine/HCl was added to each tube, and the tubes were mixed by aspirating up and down with a pipette. Yeast carrier RNA (10 uL of 10 ug/mL) was added to each tube. The samples were then spiked with 6 uL of 107 copies/mL HIV RNA in vitro transcript. The samples were mixed by aspirating and dispensing 800 uL at a time, repeated 24 times. Following mixing, the samples were then extracted as described in Example 1, i.e., by magnetically locking the iron oxide particles to the sides of the tubes and aspirating the unbound samples. The particles were washed twice with 1 mL of 86 mM glycine/HCl by aspirating and dispensing 800 uL for a total of 12 times, locking the iron oxide particles to the side of the tubes, and aspirating the fluid from tubes. The sample was then eluted from the iron oxide by adding 0.4 mL of elution buffer composed of 90 mM Bicine, 50 mM KOH, and 20 mM KPO4 to each tube, mixing by aspirating and dispensing 300 uL 12 times. Following elution, 10 microliters of yeast carrier RNA (10 mg/mL) was added to each tube. The tubes were then heated to 60° C. while being subjected to magnetic mixing for 20 minutes by alternately turning electromagnets, positioned on opposite sides of the tubes, on and off. This mixed the samples by drawing the iron oxide particles back and forth through the solution. The eluted samples were transferred to new tubes as described in Example 1, i.e., by magnetically locking the iron oxide particle to the side and aspirating the sample into new tubes and, assayed by SDA using an HIV reverse transcriptase (RT)-SDA assay system. The results are as follows:
-
Sample Temperature Proteinase K Mean Signal Clean 55° C. 9 U 2,883 65° C. 6 U 54,824 75° C. 3 U 71,577 Plasma 55° C. 3 U 1,759 6 U 13,611 9 U 12,356 65° C. 3 U 8,241 6 U 23,029 9 U 20,961 75° C. 3 U 17,650 6 U 12,767 9 U 19,554 - The results demonstrate that the pretreatment of plasma with 6-9 units of ProK results in target recovery throughout the temperature range tested (55° C. to 75° C.). Furthermore, the correlation between the temperature and the amount of ProK shows that at higher temperatures, target recovery can be achieved throughout the ProK range tested (3-9 units of ProK).
- The following experiment examined the effect of ProK and formamide and varying thermal profiles during plasma pretreatment on extraction of RNA. The RNA was extracted from the sample using iron oxide.
- First, 500 uL of EDTA anti-coagulated plasma was added to 64 tubes, each containing 40-45 mg of iron oxide. Eight of these tubes were set aside as controls, i.e. were not pretreated. Phosphate buffered saline (PBS) (300 uL) was added to eight of the tubes. The remaining forty-eight tubes received 300 uL of formamide. To each of the fifty-six tubes that contained either PBS or formamide, 20 units of ProK was added. The tubes were incubated at the temperatures and times specified in the summary table. All of the tubes were then spiked with 2,500 copies of HIV in vitro transcript to simulate a plasma sample containing 5,000 copies/mL HIV RNA. Next, 180 uL of 6 M glycine/HCl was added to each tube, and the samples were mixed by aspirating 800 uL up and down with a pipette for a total of 24 times. The iron oxide particles were then magnetically locked to the sides of the tubes, and the unbound samples were removed by aspiration. The particles were washed twice with 1 mL of 90 mM glycine/HCl by aspirating and dispensing 800 uL for a total of 12 times. After each wash, the particles were locked to the sides of the tubes and the fluid was removed by aspiration from each tube. The samples were eluted from the particles with the addition of 120 uL of elution buffer composed of 75 mM Bicine, 85 mM KOH and mixing by aspirating and dispensing 100 uL at a time for a total of 15 times. The samples were then neutralized by adding 60 uL of neutralization buffer composed of 400 mM Bicine to each tube and mixed by aspirating and dispensing 100 uL at a time for a total of 15 times. The eluted samples were transferred to new tubes as described in Example 1. The eluted samples were assayed by SDA using an HIV RT-SDA assay system. The results are as follows:
-
Mean Pretreatment Reagents Pretreatment Incubation(s) Signal None None 8597 ProK/PBS 20 min. @ 75° C. 4398 ProK + Formamide 20 min. @ 85° C. 37948 ProK + Formamide 20 min. @ 65° C. + 10 min. @ 70° C. 100894 ProK + Formamide 20 min. @ 65° C. + 10 min. @ 85° C. 63822 ProK + Formamide 30 min. @ 70° C. 99491 ProK + Formamide 20 min. @ 70° C. 74560 - The results clearly demonstrate that pre-treating plasma with ProK and formamide for the times and temperatures described gives significantly higher mean signals than not pretreating or by pretreating with ProK and PBS for 20 minutes at 75° C.
- The following experiment was conducted to compare DNA extraction efficiency from plasma when iron oxide is present during plasma pretreatment versus iron oxide being added after pretreatment.
- Human plasma (500 uL) was added to each of twelve 2 mL tubes—six containing 40 mg iron oxide and six empty tubes. ProK (5 units) was added to each tube, and the tubes were incubated for 20 minutes at 65° C. Formamide (400 uL) was added, and the tubes were incubated for 10 minutes at 70° C. The samples that were pretreated without iron oxide were transferred to six new 2 mL tubes containing 40 mg iron oxide. Next, 2,500 copies of K10 DNA plasmid containing an M. tuberculosis (TB) specific sequence were spiked into five of the six tubes that were pretreated without iron oxide present and into five of the six tubes that were pretreated with iron oxide present. To each tube was added 180 uL of 6 M glycine/HCl, followed by mixing by aspirating up and down. The iron oxide particles were magnetically locked to the sides of the tubes, and the unbound samples were aspirated. Tubes were washed twice with 5 mM glycine/HCl, locking particles to sides of tubes after each wash and aspirating fluid from tubes. Elution buffer (120 uL) composed of 105 mM KOH and 14% DMSO was added and mixed by pipetting up and down. The eluted samples were then transferred to new tubes as described in Example 1. Neutralization buffer (60 uL) composed of 350 mM Bicine and 38.5% glycerol was added and mixed by pipetting up and down. Eluted samples were amplified in a Direct TB SDA assay (DTB) to obtain DTB specific response and internal amplification control (IC) response. The results are as follows:
-
Pretreatment Mean DTB Mean IC Condition Target Signal Signal No iron oxide at 0 K10/sample 7 30639 pretreatment 2500 K10/sample 33810 20214 40 mg iron oxide at 0 K10/sample 0 19898 pretreatment 2500 K10/sample 2966 32178 - The results demonstrate that combining plasma and iron oxide after plasma pretreatment, rather than before pretreatment, improves DNA extraction efficiency from plasma as indicated by signal improvement in the TB amplification assay.
- The following experiment was conducted to compare DNA extraction efficiency from plasma when iron oxide is present during plasma pretreatment versus when iron oxide was added after pretreatment and to examine the two conditions with and without an alternating current (AC) field during mixing.
- Human plasma (500 uL) was added to each of twenty-four 2 mL tubes containing 40 mg iron oxide and to twenty-four empty 2 mL tubes. ProK (5 units) and 300 uL formamide were added to each tube. All tubes were incubated for 20 minutes at 65° C. and then for 10 minutes at 85° C. The samples that were pretreated without iron oxide were transferred to new 2 mL tubes containing 40 mg iron oxide. Next, 4,000 copies of K10 DNA plasmid containing an M. tuberculosis (TB) specific sequence was spiked into 20 of the 24 tubes that were pretreated without iron oxide present and into 20 of the 24 tubes that were pretreated with iron oxide present. Then, 150 uL of 6 M glycine/HCl was added and mixed by aspirating up and down. Twelve of the tubes pretreated with iron oxide present and 12 of the tubes pretreated without iron oxide present were mixed without an AC field at each mix step. The remaining 12 tubes pretreated with iron oxide present, as well as the remaining 12 tubes pretreated without iron oxide present, were mixed under a 30 mV AC field at each mix step. The iron oxide particles were magnetically locked to the sides of the tubes, and the unbound sample was aspirated from the tubes. The tubes were washed twice with 5 mM glycine/HCl, locking particles to sides of tubes after each wash and aspirating fluid from tubes. Next, 120 uL of elution buffer composed of 105 mM KOH and 14% DMSO was added and mixed by pipetting up and down. The eluted samples were transferred to new tubes as in Example 1. Neutralization buffer (60 uL) composed of 350 mM Bicine and 38.5% glycerol was added and mixed by pipetting up and down. Eluted samples were amplified in the Direct TB SDA assay to obtain DTB specific response and IC response. The results are as follows:
-
Pretreatment AC at Mean DTB Mean IC Cond. Mixing Target Signal Signal No iron oxide None 0 K10/sample 0 45599 4000 K10/sample 41428 40049 30 mV 0 K10/sample 4 37409 4000 K10/sample 69126 33033 40 mg iron oxide None 0 K10/sample 0 51567 4000 K10/sample 10470 44495 30 mV 0 K10/sample 0 32879 4000 K10/sample 7820 36261 - The results demonstrate that combining plasma and iron oxide after plasma pretreatment, rather than before pretreatment, improves DNA extraction efficiency from plasma as indicated by signal improvement in the TB amplification assay. Mixing in the presence of the AC field improved signal for samples that did not contain iron oxide during pretreatment.
- The following experiment was conducted to compare DNA extraction efficiency from plasma with iron oxide when plasma is diluted prior to ProK digestion with potassium phosphate buffer versus diluted after ProK digestion with water.
- Human plasma (500 uL) was added to each of twenty-four 2 mL tubes. ProK (5 units) and 400 uL of 30 mM potassium phosphate buffer were added to eight of the plasma tubes and incubated for 20 minutes at 65° C. followed by incubation for 10 minutes at 70° C. ProK (9 units) and 400 uL of 30 mM potassium phosphate buffer were added to eight of the plasma tubes and incubated for 20 minutes at 65° C. followed by incubation for 10 minutes at 70° C. ProK (5 units) was added to eight of the plasma tubes and incubated for 20 minutes at 65° C. Following the 65° C. incubation, these tubes were diluted with 400 uL of water and incubated for 10 minutes at 70° C. Potassium phosphate buffer (900 uL) was added to the remaining eight 2 mL tubes. Each of the solutions were transferred to new 2 mL tubes containing 40 mg iron oxide each. Next, 3,000 copies of K10 DNA plasmid containing an M. tuberculosis specific sequence was spiked into six of the eight tubes of each of the four conditions. The remaining two tubes of each condition were left as negative controls. Next, 180 uL of 6 M glycine/HCl was added to each tube and mixed by aspirating up and down. The iron oxide particles were magnetically locked to the sides of the tubes, and the unbound samples were aspirated. The tubes were washed twice with 5 mM glycine/HCl, locking particles to the sides of tubes after each wash and aspirating fluid from the tubes. Elution buffer (120 uL) composed of 105 mM KOH and 14% DMSO was added and mixed by pipetting up and down. The eluted samples were transferred to new tubes as described in Example 1. Neutralization buffer (60 uL) composed of 350 mM Bicine and 38.5% glycerol was added and mixed by pipetting up and down. Eluted samples were amplified in the Direct TB SDA assay to obtain DTB specific response and IC response. The results are as follows:
-
Mean DTB Mean IC Sample Dilution Target Signal Signal Buffer N/A 0 K10/sample 0 43048 3000 K10/sample 28611 42912 Plasma Pre-ProK (5 U) 0 K10/sample 15 48233 3000 K10/sample 2984 50713 Pre-ProK (9 U) 0 K10/sample 1 46930 3000 K10/sample 13126 50987 Post-ProK (5 U) 0 K10/sample 45 52543 3000 K10/sample 22893 49802 - The results demonstrate that diluting the plasma following ProK digestion improves DNA extraction efficiency from plasma as indicated by increased signal in the TB amplification assay. Results from the post-ProK dilution condition approach those of the buffer sample control.
- The following experiment was conducted to compare DNA extraction efficiency from plasma with iron oxide when plasma is diluted after ProK digestion with either formamide or water.
- To each of twelve 2 mL tubes was added 500 uL human plasma and 5 units of ProK. The tubes were incubated for 20 minutes at 65° C. Formamide (400 uL) was added to six of the tubes, and the tubes were incubated for 10 minutes at 70° C. Water (400 uL) was added to the remaining six tubes, and the tubes were incubated for 10 minutes at 70° C. Each of the solutions were transferred to new 2 mL tubes containing 40 mg iron oxide each. Next, 2,500 copies of K10 DNA plasmid, containing an M. tuberculosis specific sequence were spiked into five of the six tubes of each of the two conditions. The remaining tube of each condition was left as a negative control. Next, 180 uL of 6 M glycine/HCl was added to each of the tubes and mixed by aspirating up and down. The iron oxide particles were magnetically locked to the sides of the tubes, and the unbound samples were aspirated from the tubes. The tubes were washed twice with 5 mM glycine/HCl, locking particles to the sides of tubes after each wash and aspirating fluid from tubes. Elution buffer (120 uL) composed of 105 mM KOH and 14% DMSO was added and mixed by pipetting up and down. The eluted samples were transferred to new tubes as described in Example 1. Neutralization buffer (60 uL) composed of 350 mM Bicine and 38.5% glycerol was added and mixed by pipetting up and down. Eluted samples were amplified in the Direct TB SDA assay to obtain DTB specific response and IC responses. The results are as follows:
-
Mean DTB Mean IC Diluent Target Signal Signal Formamide 0 K10/sample 0 47601 3000 K10/sample 36305 41066 Water 0 K10/sample 0 50143 3000 K10/sample 41650 28297 - The results demonstrate that diluting the plasma following ProK digestion with either water or formamide yields similar DNA extraction efficiency from plasma as indicated by similar signal in the TB amplification assay.
- The following experiment was conducted to evaluate the effect of increasing yeast carrier RNA concentrations on RNA extraction from plasma with iron oxide.
- Human plasma was spiked with 10,000 HIV particles per mL, and 500 uL of HIV-spiked plasma was added to forty 2 mL tubes. ProK (40 units) was added to each tube. Next, 300 uL of 30 mM KP containing 0, 2.5, 5, 10, or 20 ug carrier RNA was added to the tubes (eight tubes per carrier RNA level). Given a 0.5 mL plasma sample, this translates into carrier RNA concentrations of 0, 5, 10, 20, and 40 ug per mL plasma. To serve as RNA controls, 500 uL non-spiked plasma, 40 units of ProK, 300 uL of formamide and 10,000 copies of HIV in vitro transcript were added to eight 2 mL tubes. All tubes were incubated for 30 minutes in a 70° C. water bath. Next, 180 uL of 6 M glycine/HCl was added and mixed by aspirating and dispensing 800 uL 24 times. The iron oxide particles were magnetically locked to the sides of the tubes, and the unbound samples were aspirated. The tubes were washed twice with 1 mL of 6 mM glycine/HCl by aspirating and dispensing 800 uL 15 times. The particles were locked to the side, and fluid was aspirated from the tubes. Elution buffer (120 uL) composed of 75 mM Bicine, 85 mM KOH, and 30 mM KPO4 was added to each tube and mixed by aspirating and dispensing 100 uL 15 times. The eluted samples were transferred to new tubes as described in Example 1. Neutralization buffer (60 uL) composed of 400 mM Bicine was added to each tube and mixed by aspirating and dispensing 100 uL 15 times. The iron oxide particles were magnetically locked to the sides of the tubes to allow for removal of eluted sample. The eluted samples were amplified in a HIV RT-SDA assay. The results are as follows:
-
Target CRNA/mL Plasma Mean Signal HIV Particles 0 ug 10577 HIV Particles 2.5 ug 12412 HIV Particles 5.0 ug 18008 HIV Particles 10.0 ug 18959 HIV Particles 20.0 ug 21910 HIV in vitro transcript 0 ug 21962 - The results demonstrate that the presence of carrier RNA improves recovery of specific RNA target from plasma. Carrier RNA was previously titrated into the HIV amplification assay up to 20 ug and shown to have no effect on amplification.
- The following experiment was conducted to examine the effects of activating ProK at 55° C. or 65° C. followed by a 20 minute incubation at 75° C. before binding RNA in the iron oxide system.
- A volume of 600 uL plasma from BD PPT™ tubes was added to tubes containing 40-45 mg iron oxide, and then 220 uL of 30 mM KPO4 was added to each of the tubes. ProK (6 units) was also added to each tube, and the ProK was activated by incubating the tubes for 20 minutes either in a 55° C. water bath or in a 65° C. water bath. The tubes were transferred to a 75° C. water bath and incubated for 20 minutes. The samples were cooled at room temperature for 5 minutes. Next, 180 uL of 6 M glycine/HCl was added to each tube, and the samples were pipette mixed. Next, 10 uL yeast carrier RNA (10 ug/mL) was added to each tube, followed by 6 uL HIV stock RNA (107 copies/ml) and pipette mixed. The unbound samples were removed from the tubes by locking iron oxide particles to the side of tube and aspirating the solution to waste. The particles were washed three times with 1000 uL wash solution (86 mM glycine/HCl) by pipette mixing, locking iron oxide particles to the side of each tube, and aspirating unbound solution. The samples were then eluted by adding 400 uL elution buffer (90 mM Bicine, 50 mM KOH and 20 mM KPO4) to each tube and conducting 12 cycles of aspiration mixing, followed by 20 minutes of magnetic mixing at 60° C., followed by a second round of 12-cycle aspiration mixing. Yeast carrier RNA (10 ug) was added to each tube. The target was added to pre-assay spiked control samples. The samples were removed to new tubes as described in Example 1 and assayed by an HIV RT-SDA assay. The results are as follows:
-
Specimen Buffer Plasma Buffer Plasma Pro K 6 U 6 U 6 U 6 U Pro K Activation 55° C. 55° C. 65° C. 65° C. Pro K Incubation 75° C. 75° C. 75° C. 75° C. Signal 49816 6182 28052 70729 52798 31904 74120 73942 56186 53210 76484 58029 55034 57928 67257 51201 Mean Signal 53459 37306 61478 63475 % CV 5 63 37 17 - The pretreating of plasma with ProK at elevated temperatures (55° C. to 65° C. activation temperature followed by 75° C. incubation temperature) demonstrates extraction efficiency as indicated by positive assay signals.
- This experiment was conducted to extract RNA from whole blood and examine the use of additional wash steps to decrease carryover of inhibitory components into the elution step.
- Whole blood samples (500 uL) were each pretreated with 20 units of ProK and 300 uL of formamide for 20 minutes at 65° C. and 10 minutes at 85° C. One set of samples was pretreated with a 6-cycle wash for two washes and another set with a 9-cycle wash for three washes. The samples were eluted with 85 mM KOH/75 mM Bicine, neutralized with 400 mM Bicine, and detected with in the HIV gag gene RT-SDA amplification system. The results are as follows:
-
Wash 2X WASH and 6 CYCLES 3X WASH and 9 CYCLES COPIES/ML Signal Mean Signal Signal Mean Signal 0 64 241 0 35 151 0 27 474 0 119 61 57 231 5,000 6798 1151 5,000 22268 2433 5,000 2831 4031 5,000 42 7985 45 1915 25,000 11154 30543 25,000 7470 53000 25,000 23408 42699 25,000 20112 15536 39496 41435 50,000 9982 35527 50,000 47798 81777 50,000 15862 27265 50,000 7165 20202 53345 49479 - The results demonstrate that the additional wash improves assay signal indicating reduced carryover of inhibitory substances with increased washing.
- While the invention has been described with some specificity, modifications apparent to those with ordinary skill in the art may be made without departing from the scope of the invention. Various features of the invention are set forth in the following claims.
Claims (34)
1. A method of treating a biological sample for extraction of nucleic acid therefrom comprising mixing the sample with at least one protein denaturant and heating the mixture stepwise.
2. The method of claim 1 wherein the stepwise heating is in a temperature range of about 55° C. to about 85° C.
3. A method of treating a biological sample for extraction of nucleic acid therefrom comprising treating the sample with at least one protein denaturant to form a reaction mixture and diluting the reaction mixture with a diluent.
4. The method of claim 3 wherein the diluent is selected from the group consisting of water, aqueous buffer solutions and aprotic solvents.
5. The method of claim 3 wherein the method is carried out at a temperature at or above about 4° C.
6. The method of claim 5 wherein the method is carried out in a temperature range of about 25° C. to about 95° C.
7. A reaction mixture for treating a biological sample for extraction of nucleic acid therefrom, wherein said reaction mixture comprises at least one protein denaturant and at least one aprotic solvent.
8. The reaction mixture of claim 7 wherein the protein denaturant is selected from the group consisting of proteolytic enzymes, detergents, surfactants, solvents, amides, reducing agents, bases, protein denaturing salts and combinations thereof.
9. The reaction mixture of claim 8 wherein the protein denaturant is a proteolytic enzyme selected from the group consisting of proteinase K, pronase, pepsin, trypsin, chymotrypsin, carboxypeptidase and elastase.
10. The reaction mixture of claim 9 wherein the proteolytic enzyme is proteinase K.
11. The reaction mixture of claim 8 wherein the protein denaturant is a detergent selected from the group consisting of sodium dodecyl sulfate, lithium dodecyl sulfate, polyethylene glycol sorbitan monolaurate, polyethylene glycol sorbitan monooleate, NP-40, dodecyl trimethyl ammonium bromide, cetyl trimethyl ammonium bromide, 3[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate, and polyethylene glycol tert-octylphenyl ether.
12. The reaction mixture of claim 8 wherein the protein denaturant is a surfactant.
13. The reaction mixture of claim 8 wherein the protein denaturant is a solvent selected from the group consisting of phenol, chloroform and isoamylalcohol.
14. The reaction mixture of claim 8 wherein the protein denaturant is an amide selected from the group consisting of N-ethylacetamide, N-butylacetamide and N,N-dimethylacetamide.
15. The reaction mixture of claim 8 wherein the protein denaturant is a reducing agent selected from the group consisting of glutathione, β-mercatoethanol and dithiothreitol.
16. The reaction mixture of claim 8 wherein the protein denaturant is a base selected from the group consisting of KOH, NaOH, NH4OH and Ca(OH)2.
17. The reaction mixture of claim 8 wherein the protein denaturant is a protein denaturing salt selected from the group consisting of NaCl, KCl, LiCl, NH4Cl, (NH4)2SO4 and perchlorate salt.
18. The reaction mixture of claim 7 wherein the aprotic solvent is selected from the group consisting of formamide, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, acetronitrile, benzene, toluene, acetone, cyclohexane, n-heptane, sulfur dioxide and hexamethylphosphoramide.
19. The reaction mixture of claim 18 wherein the aprotic solvent is formamide.
20. The reaction mixture of claim 7 wherein the treatment is carried out at a temperature at or above about 4° C.
21. The reaction mixture of claim 20 wherein the treatment is carried out in a temperature range of about 25° C. to about 95° C.
22. The reaction mixture of claim 20 wherein the treatment is carried out in a temperature range of about 70° C. to about 85° C.
23. The reaction mixture of claim 7 wherein the treatment is carried out by stepwise heating in a temperature range of about 55° C. to about 85° C.
24. The reaction mixture of claim 9 wherein the concentration of proteinase K is about 1 to about 100 units per milliliter of biological sample.
25. The reaction mixture of claim 20 wherein the concentration of formamide is about 10% to about 80% by volume.
26. The reaction mixture of claim 7 further comprising a solid support.
27. The reaction mixture of claim 26 wherein the solid support is selected from the group consisting of iron oxide, silica-coated particles, silica-coated membranes, glass fiber mats, glass membranes, glasses, zeolites and ceramics.
28. A nucleic acid extracted from a biological sample, wherein said nucleic acid is extracted by treating the sample with at least one protein denaturant and at least one aprotic solvent.
29. The nucleic acid of claim 28 wherein the protein denaturant is selected from the group consisting of proteolytic enzymes, detergents, surfactants, solvents, amides, reducing agents, bases, protein denaturing salts and combinations thereof.
30. The nucleic acid of claim 29 wherein the protein denaturant is a proteolytic enzyme selected from the group consisting of proteinase K, pronase, pepsin, trypsin, chymotrypsin, carboxypeptidase and elastase.
31. The nucleic acid of claim 30 wherein the proteolytic enzyme is proteinase K.
32. The nucleic acid of claim 29 wherein the aprotic solvent is selected from the group consisting of formamide, dimethylformamide, dimethyl sulfoxide, dimethylacetamide, acetronitrile, benzene, toluene, acetone, cyclohexane and n-heptane, sulfur dioxide and hexamethylphosphoramide.
33. The nucleic acid of claim 32 wherein the aprotic solvent is formamide.
34. The nucleic acid of claim 28 wherein the nucleic acid is RNA.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/778,501 US20100286380A1 (en) | 2003-02-06 | 2010-05-12 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/359,179 US7601491B2 (en) | 2003-02-06 | 2003-02-06 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
US12/359,854 US7727727B2 (en) | 2003-02-06 | 2009-01-26 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
US12/778,501 US20100286380A1 (en) | 2003-02-06 | 2010-05-12 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/359,854 Division US7727727B2 (en) | 2003-02-06 | 2009-01-26 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
Publications (1)
Publication Number | Publication Date |
---|---|
US20100286380A1 true US20100286380A1 (en) | 2010-11-11 |
Family
ID=32823786
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/359,179 Expired - Fee Related US7601491B2 (en) | 2003-02-06 | 2003-02-06 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
US12/359,854 Expired - Fee Related US7727727B2 (en) | 2003-02-06 | 2009-01-26 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
US12/778,501 Abandoned US20100286380A1 (en) | 2003-02-06 | 2010-05-12 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/359,179 Expired - Fee Related US7601491B2 (en) | 2003-02-06 | 2003-02-06 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
US12/359,854 Expired - Fee Related US7727727B2 (en) | 2003-02-06 | 2009-01-26 | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor |
Country Status (5)
Country | Link |
---|---|
US (3) | US7601491B2 (en) |
EP (1) | EP1590489A4 (en) |
JP (1) | JP2006517298A (en) |
CA (1) | CA2515040A1 (en) |
WO (1) | WO2004072228A2 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012083198A2 (en) * | 2010-12-17 | 2012-06-21 | University Of Utah Research Foundation | Methods and compositions for purifying dna |
Families Citing this family (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6884357B2 (en) | 1995-02-21 | 2005-04-26 | Iqbal Waheed Siddiqi | Apparatus and method for processing magnetic particles |
WO2005007852A2 (en) * | 2003-07-09 | 2005-01-27 | Genvault Corporation | Room temperature elution of nucleic acids |
US9267167B2 (en) * | 2004-06-28 | 2016-02-23 | Becton, Dickinson And Company | Dissolvable films and methods including the same |
US20060024776A1 (en) * | 2004-08-02 | 2006-02-02 | Mcmillian Ray | Magnetic particle capture of whole intact organisms from clinical samples |
JP2008104378A (en) * | 2006-10-24 | 2008-05-08 | Kanmonkai:Kk | Method for detecting pathogenic crustacean virus |
DE102007025277A1 (en) * | 2007-05-31 | 2008-12-04 | Qiagen Gmbh | Method for stabilizing a biological sample |
ES2665280T3 (en) * | 2007-06-29 | 2018-04-25 | Becton, Dickinson And Company | Methods for the extraction and purification of components of biological samples |
DE102007035250A1 (en) * | 2007-07-27 | 2009-01-29 | Qiagen Gmbh | Method for separating non-protein-containing biomolecules, in particular nucleic acids from protein-containing samples |
WO2009126649A2 (en) * | 2008-04-07 | 2009-10-15 | Life Bioscience, Inc. | Method of providing particles having biological-binding areas for biological applications |
JP5592357B2 (en) | 2008-05-27 | 2014-09-17 | ダコ・デンマーク・エー/エス | Compositions and methods for detection of chromosomal abnormalities using novel hybridization buffers |
JP2012502632A (en) * | 2008-09-17 | 2012-02-02 | ジーイー・ヘルスケア・バイオサイエンス・コーポレイション | Small RNA isolation method |
EP2361314B1 (en) * | 2008-10-27 | 2015-03-18 | Becton Dickinson and Company | Assay for chlamydia trachomatis by amplification and detection of chlamydia trachomatis pmpa gene |
US9416426B2 (en) | 2008-10-27 | 2016-08-16 | Becton, Dickinson And Company | Assay for Chlamydia trachomatis by amplification and detection of Chlamydia trachomatis pmpA gene |
JP5570422B2 (en) * | 2009-01-16 | 2014-08-13 | アークレイ株式会社 | Nucleic acid sample production method and nucleic acid amplification product production method using the same |
US20120111727A1 (en) * | 2009-01-26 | 2012-05-10 | Vladislav Dolnik | Capillary sieving electrophoresis with a cationic surfactant for size separation of proteins |
WO2010097656A1 (en) | 2009-02-26 | 2010-09-02 | Dako Denmark A/S | Compositions and methods for performing a stringent wash step in hybridization applications |
US8222397B2 (en) | 2009-08-28 | 2012-07-17 | Promega Corporation | Methods of optimal purification of nucleic acids and kit for use in performing such methods |
US8039613B2 (en) | 2009-08-28 | 2011-10-18 | Promega Corporation | Methods of purifying a nucleic acid and formulation and kit for use in performing such methods |
ES2398646T3 (en) | 2010-07-24 | 2013-03-20 | F. Hoffmann-La Roche Ag | Stabilization of interleukin-6 in serum solutions |
US20130261003A1 (en) | 2010-08-06 | 2013-10-03 | Ariosa Diagnostics, In. | Ligation-based detection of genetic variants |
US11203786B2 (en) | 2010-08-06 | 2021-12-21 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US20140342940A1 (en) | 2011-01-25 | 2014-11-20 | Ariosa Diagnostics, Inc. | Detection of Target Nucleic Acids using Hybridization |
US11031095B2 (en) | 2010-08-06 | 2021-06-08 | Ariosa Diagnostics, Inc. | Assay systems for determination of fetal copy number variation |
US20120034603A1 (en) | 2010-08-06 | 2012-02-09 | Tandem Diagnostics, Inc. | Ligation-based detection of genetic variants |
US10167508B2 (en) | 2010-08-06 | 2019-01-01 | Ariosa Diagnostics, Inc. | Detection of genetic abnormalities |
US8700338B2 (en) | 2011-01-25 | 2014-04-15 | Ariosa Diagnosis, Inc. | Risk calculation for evaluation of fetal aneuploidy |
US10533223B2 (en) | 2010-08-06 | 2020-01-14 | Ariosa Diagnostics, Inc. | Detection of target nucleic acids using hybridization |
US20130040375A1 (en) | 2011-08-08 | 2013-02-14 | Tandem Diagnotics, Inc. | Assay systems for genetic analysis |
US9994897B2 (en) | 2013-03-08 | 2018-06-12 | Ariosa Diagnostics, Inc. | Non-invasive fetal sex determination |
US10131947B2 (en) | 2011-01-25 | 2018-11-20 | Ariosa Diagnostics, Inc. | Noninvasive detection of fetal aneuploidy in egg donor pregnancies |
US8756020B2 (en) | 2011-01-25 | 2014-06-17 | Ariosa Diagnostics, Inc. | Enhanced risk probabilities using biomolecule estimations |
US11270781B2 (en) | 2011-01-25 | 2022-03-08 | Ariosa Diagnostics, Inc. | Statistical analysis for non-invasive sex chromosome aneuploidy determination |
CN102250876B (en) * | 2011-05-18 | 2014-08-13 | 李学敬 | Method for separating and purifying RNA in biological material |
US8712697B2 (en) | 2011-09-07 | 2014-04-29 | Ariosa Diagnostics, Inc. | Determination of copy number variations using binomial probability calculations |
WO2013045458A1 (en) | 2011-09-26 | 2013-04-04 | Preanalytix Gmbh | Stabilisation and isolation of extracellular nucleic acids |
US11021733B2 (en) | 2011-09-26 | 2021-06-01 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
EP2761020B1 (en) * | 2011-09-26 | 2018-06-13 | Qiagen GmbH | Stabilisation and isolation of extracellular nucleic acids |
EP3252173A1 (en) * | 2011-10-21 | 2017-12-06 | Dako Denmark A/S | Hybridization compositions and methods |
KR20130140934A (en) * | 2012-05-09 | 2013-12-26 | 삼성전자주식회사 | Methods for extracting directly microrna from microvesicle in cell line, cell culture or body fluid |
US10289800B2 (en) | 2012-05-21 | 2019-05-14 | Ariosa Diagnostics, Inc. | Processes for calculating phased fetal genomic sequences |
EP2875156A4 (en) | 2012-07-19 | 2016-02-24 | Ariosa Diagnostics Inc | Multiplexed sequential ligation-based detection of genetic variants |
CA2884915C (en) | 2012-09-25 | 2022-05-17 | Qiagen Gmbh | Stabilisation of biological samples |
CN103852527B (en) * | 2012-12-05 | 2015-05-13 | 中国科学院大连化学物理研究所 | High-flux protein sample pre-treatment device |
ES2865124T3 (en) | 2013-03-15 | 2021-10-15 | Abbott Molecular Inc | One-step procedure for the purification of nucleic acids |
US20160281133A1 (en) * | 2013-03-18 | 2016-09-29 | Qiagen Gmbh | Stabilization and isolation of extracellular nucleic acids |
US11525155B2 (en) | 2013-03-18 | 2022-12-13 | Qiagen Gmbh | Stabilisation of biological samples |
KR20150017611A (en) * | 2013-08-07 | 2015-02-17 | 삼성전자주식회사 | Method for separation of nucleic acid from cells |
JP6574207B2 (en) | 2014-05-05 | 2019-09-11 | スリーディー グラス ソリューションズ,インク3D Glass Solutions,Inc | 2D and 3D inductors, antennas, and transformers for manufacturing photoactive substrates |
US10093989B2 (en) | 2014-10-20 | 2018-10-09 | Gen-Probe Incorporated | Red blood cell lysis solution |
US10070533B2 (en) | 2015-09-30 | 2018-09-04 | 3D Glass Solutions, Inc. | Photo-definable glass with integrated electronics and ground plane |
EP3377645B1 (en) | 2015-11-20 | 2023-10-04 | Qiagen GmbH | Method of preparing sterilized compositions for stabilization of extracellular nucleic acids |
JP7071609B2 (en) | 2016-02-25 | 2022-05-19 | スリーディー グラス ソリューションズ,インク | Capacitor array for manufacturing 3D capacitors and photoactive substrates |
WO2017177171A1 (en) | 2016-04-08 | 2017-10-12 | 3D Glass Solutions, Inc. | Methods of fabricating photosensitive substrates suitable for optical coupler |
WO2017189746A1 (en) | 2016-04-27 | 2017-11-02 | Gen-Probe Incorporated | Blood cell lysis reagent |
WO2018200804A1 (en) | 2017-04-28 | 2018-11-01 | 3D Glass Solutions, Inc. | Rf circulator |
AU2018297035B2 (en) | 2017-07-07 | 2021-02-25 | 3D Glass Solutions, Inc. | 2D and 3D RF lumped element devices for RF system in a package photoactive glass substrates |
KR102614826B1 (en) | 2017-12-15 | 2023-12-19 | 3디 글래스 솔루션즈 인코포레이티드 | Coupled transmission line resonate rf filter |
WO2019136024A1 (en) | 2018-01-04 | 2019-07-11 | 3D Glass Solutions, Inc. | Impedance matching conductive structure for high efficiency rf circuits |
EP3643148A4 (en) | 2018-04-10 | 2021-03-31 | 3D Glass Solutions, Inc. | Rf integrated power condition capacitor |
KR102161984B1 (en) | 2018-05-29 | 2020-10-07 | 3디 글래스 솔루션즈 인코포레이티드 | Low insertion loss RF transmission line |
KR102322938B1 (en) | 2018-09-17 | 2021-11-09 | 3디 글래스 솔루션즈 인코포레이티드 | High Efficiency Compact Slot Antenna with Ground Plane |
JP7257707B2 (en) | 2018-12-28 | 2023-04-14 | スリーディー グラス ソリューションズ,インク | Annular capacitor RF, microwave and MM wave systems |
JP7241433B2 (en) | 2018-12-28 | 2023-03-17 | スリーディー グラス ソリューションズ,インク | Heterogeneous Integration for RF, Microwave and MM Wave Systems on Photoactive Glass Substrates |
US11373908B2 (en) | 2019-04-18 | 2022-06-28 | 3D Glass Solutions, Inc. | High efficiency die dicing and release |
CN113025608A (en) * | 2019-12-09 | 2021-06-25 | 深圳市真迈生物科技有限公司 | Cell lysate, kit and application |
GB2595572A (en) * | 2020-04-15 | 2021-12-01 | Vosbio Inc | Methods, devices and kits for preparing nucleic acid samples for storage and analysis |
US11908617B2 (en) | 2020-04-17 | 2024-02-20 | 3D Glass Solutions, Inc. | Broadband induction |
CN114292904B (en) * | 2021-12-25 | 2022-11-01 | 武汉承启医学检验实验室有限公司 | Method for optimizing ctDNA detection accuracy |
Citations (92)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797202A (en) * | 1971-08-27 | 1974-03-19 | Gen Electric | Microporous/non-porous composite membranes |
US3970518A (en) * | 1975-07-01 | 1976-07-20 | General Electric Company | Magnetic separation of biological particles |
US3985649A (en) * | 1974-11-25 | 1976-10-12 | Eddelman Roy T | Ferromagnetic separation process and material |
US4018886A (en) * | 1975-07-01 | 1977-04-19 | General Electric Company | Diagnostic method and device employing protein-coated magnetic particles |
US4141687A (en) * | 1976-03-12 | 1979-02-27 | Technicon Instruments Corporation | Automatic apparatus and method for the assay of fluid samples |
US4230685A (en) * | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
US4272510A (en) * | 1976-04-26 | 1981-06-09 | Smith Kendall O | Magnetic attraction transfer process for use in solid phase radioimmunoassays and in other assay methods |
US4672040A (en) * | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
US4695393A (en) * | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
US4774265A (en) * | 1982-04-23 | 1988-09-27 | Sintef | Process for preparing magnetic polymer particles |
US4855045A (en) * | 1982-01-14 | 1989-08-08 | Reed Thomas A | Method and apparatus for the separation of organic substances from a suspension or solution |
US4900677A (en) * | 1986-09-26 | 1990-02-13 | E. I. Du Pont De Nemours And Company | Process for rapid isolation of high molecular weight DNA |
US4910148A (en) * | 1987-02-10 | 1990-03-20 | Dynal A. S. | Magnetic separation of magnetized particles from biological fluids |
US4923978A (en) * | 1987-12-28 | 1990-05-08 | E. I. Du Pont De Nemours & Company | Process for purifying nucleic acids |
US4935147A (en) * | 1985-12-20 | 1990-06-19 | Syntex (U.S.A.) Inc. | Particle separation method |
US4935342A (en) * | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
US4946952A (en) * | 1987-04-24 | 1990-08-07 | Hoffmann-La Roche Inc. | Process for isolating nucleic acids |
US4988618A (en) * | 1987-11-16 | 1991-01-29 | Gene-Trak Systems | Magnetic separation device and methods for use in heterogeneous assays |
US5010183A (en) * | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
US5043070A (en) * | 1989-11-13 | 1991-08-27 | Board Of Control Of Michigan Technological University | Magnetic solvent extraction |
US5076950A (en) * | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
US5084169A (en) * | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
US5130423A (en) * | 1990-07-13 | 1992-07-14 | Microprobe Corporation | Non-corrosive compositions and methods useful for the extraction of nucleic acids |
US5129936A (en) * | 1990-07-30 | 1992-07-14 | Wilson Harold W | Processes for the preparation of acid fortified paramagnetic iron sulfate salt compounds for use in the treatment of agricultural soils |
US5167811A (en) * | 1984-11-28 | 1992-12-01 | Trustees Of The University Of Pennsylvania | Affinity chromatography using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed |
US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
US5242833A (en) * | 1991-03-20 | 1993-09-07 | Reference Diagnostics, Inc. | Lipid fractionation |
US5279936A (en) * | 1989-12-22 | 1994-01-18 | Syntex (U.S.A.) Inc. | Method of separation employing magnetic particles and second medium |
US5318914A (en) * | 1991-07-22 | 1994-06-07 | Pasteur Sanofi Diagnostics | Process and magnetic device for immunological analysis of a solid phase |
US5336760A (en) * | 1989-09-14 | 1994-08-09 | Baxter International Inc. | Method and useful apparatus for preparing pharmaceutical compositions |
US5340749A (en) * | 1988-04-26 | 1994-08-23 | Nippon Telegraph And Telephone Corporation | Method for collecting and preparing specimens for immune reactions |
US5370993A (en) * | 1987-05-19 | 1994-12-06 | Syntex (U.S.A.) Inc. | Reversible agglutination mediators |
US5386024A (en) * | 1993-02-10 | 1995-01-31 | Gen-Probe Incorporated | Method to prepare nucleic acids from a biological sample using low pH and acid protease |
US5395688A (en) * | 1987-10-26 | 1995-03-07 | Baxter Diagnostics Inc. | Magnetically responsive fluorescent polymer particles |
US5433847A (en) * | 1989-11-01 | 1995-07-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Radial flow chromatography |
US5438128A (en) * | 1992-02-07 | 1995-08-01 | Millipore Corporation | Method for rapid purifiction of nucleic acids using layered ion-exchange membranes |
US5464752A (en) * | 1987-03-13 | 1995-11-07 | Coulter Corporation | Automated analyzer for screening cells or formed bodies for enumeration of populations expressing selected characteristics |
US5474914A (en) * | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
US5491068A (en) * | 1991-02-14 | 1996-02-13 | Vicam, L.P. | Assay method for detecting the presence of bacteria |
US5512439A (en) * | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5518890A (en) * | 1992-11-20 | 1996-05-21 | Mccormick & Company, Inc. | Method and apparatus for the quantitation and separation of contaminants from particulate materials |
US5523231A (en) * | 1990-02-13 | 1996-06-04 | Amersham International Plc | Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules |
US5541072A (en) * | 1994-04-18 | 1996-07-30 | Immunivest Corporation | Method for magnetic separation featuring magnetic particles in a multi-phase system |
US5543289A (en) * | 1988-12-28 | 1996-08-06 | Miltenyi; Stefan | Methods and materials for improved high gradient magnetic separation of biological materials |
US5582988A (en) * | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
US5625053A (en) * | 1994-08-26 | 1997-04-29 | Board Of Regents For Northern Illinois Univ. | Method of isolating purified plasmid DNA using a nonionic detergent, solution |
US5637687A (en) * | 1993-08-31 | 1997-06-10 | Wiggins; James C. | Methods and compositions for isolating nucleic acids |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5647994A (en) * | 1993-06-21 | 1997-07-15 | Labsystems Oy | Method and apparatus for separating magnetic particles from a solution |
US5652141A (en) * | 1990-10-26 | 1997-07-29 | Oiagen Gmbh | Device and process for isolating nucleic acids from cell suspension |
US5652348A (en) * | 1994-09-23 | 1997-07-29 | Massey University | Chromatographic resins and methods for using same |
US5665554A (en) * | 1994-06-09 | 1997-09-09 | Amersham International Plc | Magnetic bead precipitation method |
US5674997A (en) * | 1993-09-27 | 1997-10-07 | Becton Dickinson And Company | DNA purification on modified siligates |
US5681478A (en) * | 1989-12-07 | 1997-10-28 | Diatec Instruments A/S | Method and apparatus for magnetically separating and resuspending super-paramagnetic particles in a solution |
US5684712A (en) * | 1991-10-23 | 1997-11-04 | Cellpro, Inc. | Apparatus and method for cell separation |
US5693785A (en) * | 1992-02-13 | 1997-12-02 | Becton, Dickinson And Company | Purification of DNA on Hydroxylated Silicas |
US5705062A (en) * | 1993-09-17 | 1998-01-06 | Hoffmann-La Roche Inc. | Analytical device for separating magnetic microparticles from suspensions |
US5705628A (en) * | 1994-09-20 | 1998-01-06 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
US5763203A (en) * | 1993-03-11 | 1998-06-09 | Sinvent As | Immobilization and separation of cells and other particles |
US5766852A (en) * | 1993-11-16 | 1998-06-16 | Becton, Dickinson And Company | Process for lysing mycobacteria |
US5773307A (en) * | 1993-09-20 | 1998-06-30 | Bio Merieux | Method and device for determining an analyte in a sample |
US5786208A (en) * | 1993-11-29 | 1998-07-28 | Gen-Probe Incorporated | Method for extracting nucleic acids from a wide range of organisms |
US5834197A (en) * | 1994-05-11 | 1998-11-10 | Genera Technologies Limited | Methods of capturing species from liquids and assay procedures |
US5897783A (en) * | 1992-09-24 | 1999-04-27 | Amersham International Plc | Magnetic separation method |
US5907035A (en) * | 1996-05-23 | 1999-05-25 | Baxter Biotech Technology Sarl | Aqueous two-phase metal affinity partitioning protein purification system |
US5916539A (en) * | 1993-03-02 | 1999-06-29 | Silica Gel Ges. M.B.H. | Superparamagnetic particles, process for producing the same and their use |
US5922284A (en) * | 1995-05-09 | 1999-07-13 | Fujirebio Inc. | Method and apparatus for agglutination immunoassay |
US5925573A (en) * | 1995-03-21 | 1999-07-20 | Bio Merieux | Method and device for the determination of an analyte using super paramagnetic reactive particles |
US5928958A (en) * | 1994-07-27 | 1999-07-27 | Pilgrimm; Herbert | Superparamagnetic particles, process for their manufacture and usage |
US5945525A (en) * | 1995-07-07 | 1999-08-31 | Toyo Boseki Kabushiki Kaisha | Method for isolating nucleic acids using silica-coated magnetic particles |
US5955268A (en) * | 1996-04-26 | 1999-09-21 | Abbott Laboratories | Method and reagent for detecting multiple nucleic acid sequences in a test sample |
US5973138A (en) * | 1998-10-30 | 1999-10-26 | Becton Dickinson And Company | Method for purification and manipulation of nucleic acids using paramagnetic particles |
US5981235A (en) * | 1996-07-29 | 1999-11-09 | Promega Corporation | Methods for isolating nucleic acids using alkaline protease |
US5990302A (en) * | 1996-07-12 | 1999-11-23 | Toyo Boseki Kabushiki Kaisha | Method for isolating ribonucleic acid |
US5998224A (en) * | 1997-05-16 | 1999-12-07 | Abbott Laboratories | Magnetically assisted binding assays utilizing a magnetically responsive reagent |
US6008002A (en) * | 1997-09-29 | 1999-12-28 | Bodey; Bela | Immunomagnetic detection and isolation of cancer cells |
US6020211A (en) * | 1994-10-20 | 2000-02-01 | Labsystems Oy | Separation of magnetic microparticles involving a preconcentration step |
US6020210A (en) * | 1988-12-28 | 2000-02-01 | Miltenvi Biotech Gmbh | Methods and materials for high gradient magnetic separation of biological materials |
US6024881A (en) * | 1998-08-11 | 2000-02-15 | Just; Gerard A. | Magnetic absorption treatment of fluid phases |
US6027945A (en) * | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
US6033574A (en) * | 1995-02-21 | 2000-03-07 | Siddiqi; Iqbal W. | Method for mixing and separation employing magnetic particles |
US6040192A (en) * | 1993-02-01 | 2000-03-21 | Labsystems Oy | Method and means for magnetic particle specific binding assay |
US6096554A (en) * | 1994-06-15 | 2000-08-01 | Precision System Science Co., Ltd. | Magnetic material attracting/releasing control method making use of a pipette device and various types of analyzer using the method |
US6099738A (en) * | 1997-12-17 | 2000-08-08 | Micromag Corporation | Method and system for removing solutes from a fluid using magnetically conditioned coagulation |
US6143578A (en) * | 1996-05-10 | 2000-11-07 | Bayer Corporation | Method and apparatus for wash, resuspension, recollection and localization of magnetizable particles in assays using magnetic separation technology |
US6146511A (en) * | 1998-01-30 | 2000-11-14 | The Perkin-Elmer Corporation | Electrophoretic nucleic acid purification method |
US6187270B1 (en) * | 1994-07-07 | 2001-02-13 | Roche Diagnostics Gmbh | Device and method for the separation of magnetic microparticles |
US6210881B1 (en) * | 1996-12-30 | 2001-04-03 | Becton, Dickinson And Company | Method for reducing inhibitors of nucleic acid hybridization |
US6265164B1 (en) * | 1998-03-26 | 2001-07-24 | Biochain Institute, Inc. | Compositions and methods for directly and rapidly analyzing the biochemical components of microorganisms |
US20010018513A1 (en) * | 1997-12-06 | 2001-08-30 | Baker Matthew John | Isolation of nucleic acids |
US6294342B1 (en) * | 1999-09-29 | 2001-09-25 | Abbott Laboratories | Magnetically assisted binding assays utilizing a magnetically responsive reagent |
US6355792B1 (en) * | 1998-02-04 | 2002-03-12 | Merck Patent Gesellschaft | Method for isolating and purifying nucleic acids |
Family Cites Families (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6267965B1 (en) | 1981-12-24 | 2001-07-31 | Virogenetics Corporation | Recombinant poxvirus—cytomegalovirus compositions and uses |
CH663476A5 (en) | 1985-07-08 | 1987-12-15 | Serono Diagnostics Ltd | ENCLOSURE FOR THE DETERMINATION OF ANTIBODIES OR ANTIGENS IN A BIOLOGICAL LIQUID. |
ZA877772B (en) | 1986-10-23 | 1988-04-20 | Amoco Corporation | Target and background capture methods and apparatus for affinity assays |
DE3639949A1 (en) | 1986-11-22 | 1988-06-09 | Diagen Inst Molekularbio | METHOD FOR SEPARATING LONG CHAIN NUCLEIC ACIDS |
NL8900725A (en) | 1989-03-23 | 1990-10-16 | Az Univ Amsterdam | METHOD AND COMBINATION OF AGENTS FOR INSULATING NUCLEIC ACID. |
CA2067711C (en) | 1991-05-03 | 2000-08-08 | Daniel Lee Woodard | Solid phase extraction purification of dna |
EP0580305B1 (en) | 1992-07-02 | 1999-09-22 | Edge Biosystems, Inc. | Method and material for purification of nucleic acids |
DE4321904B4 (en) * | 1993-07-01 | 2013-05-16 | Qiagen Gmbh | Method for chromatographic purification and separation of nucleic acid mixtures |
EP0741141A2 (en) | 1995-05-04 | 1996-11-06 | Hewlett-Packard Company | Method of purifying ologonucleotide from biological samples |
EP1260595B1 (en) | 1995-07-07 | 2006-09-13 | Toyo Boseki Kabushiki Kaisha | Nucleic acid-bondable magnetic carrier and method for isolating nucleic acid using the same |
CA2259657C (en) * | 1996-07-01 | 2009-04-14 | Universite De Montreal | Identification of a transforming fragment of herpes simplex type 2 and detection thereof in clinical specimens |
EP1712921A2 (en) | 1997-09-29 | 2006-10-18 | F.Hoffmann-La Roche Ag | Apparatus for separating magnetic particles |
DE19743518A1 (en) | 1997-10-01 | 1999-04-15 | Roche Diagnostics Gmbh | Automated, universally applicable sample preparation method |
US6337215B1 (en) | 1997-12-01 | 2002-01-08 | International Business Machines Corporation | Magnetic particles having two antiparallel ferromagnetic layers and attached affinity recognition molecules |
WO1999029703A2 (en) | 1997-12-06 | 1999-06-17 | Dna Research Instruments Limited | Isolation of nucleic acids |
EP0937497B9 (en) | 1997-12-25 | 2003-10-29 | Tosoh Corporation | Magnetic carrier, preparation thereof, and method of extraction of nucleic acid |
US6534262B1 (en) | 1998-05-14 | 2003-03-18 | Whitehead Institute For Biomedical Research | Solid phase technique for selectively isolating nucleic acids |
WO2000050564A2 (en) * | 1999-02-26 | 2000-08-31 | Myriad Genetics, Inc. | Method for extracting dna from dried specimens |
JP4045475B2 (en) | 1999-09-06 | 2008-02-13 | 東洋紡績株式会社 | Nucleic acid / protein purification equipment |
US6936414B2 (en) | 1999-12-22 | 2005-08-30 | Abbott Laboratories | Nucleic acid isolation method and kit |
US6672458B2 (en) | 2000-05-19 | 2004-01-06 | Becton, Dickinson And Company | System and method for manipulating magnetically responsive particles fluid samples to collect DNA or RNA from a sample |
US7001724B1 (en) * | 2000-11-28 | 2006-02-21 | Applera Corporation | Compositions, methods, and kits for isolating nucleic acids using surfactants and proteases |
EP1349951A4 (en) | 2001-01-09 | 2005-08-24 | Whitehead Biomedical Inst | Methods and reagents for the isolation of nucleic acids |
GB2374082A (en) | 2001-04-04 | 2002-10-09 | Procter & Gamble | Particles for a detergent product |
US7214427B2 (en) | 2002-03-21 | 2007-05-08 | Aviva Biosciences Corporation | Composite beads comprising magnetizable substance and electro-conductive substance |
CN1653338A (en) | 2002-05-17 | 2005-08-10 | 贝克顿·迪金森公司 | Automated system for isolating, amplifying and detecting a target nucleic acid sequence |
US7517697B2 (en) * | 2003-02-05 | 2009-04-14 | Applied Biosystems, Llc | Compositions and methods for preserving RNA in biological samples |
US20040157219A1 (en) | 2003-02-06 | 2004-08-12 | Jianrong Lou | Chemical treatment of biological samples for nucleic acid extraction and kits therefor |
US20050239091A1 (en) | 2004-04-23 | 2005-10-27 | Collis Matthew P | Extraction of nucleic acids using small diameter magnetically-responsive particles |
CA2575784A1 (en) | 2004-08-03 | 2006-02-16 | Becton, Dickinson And Company | Use of magnetic material to fractionate samples |
-
2003
- 2003-02-06 US US10/359,179 patent/US7601491B2/en not_active Expired - Fee Related
-
2004
- 2004-02-06 CA CA002515040A patent/CA2515040A1/en not_active Abandoned
- 2004-02-06 JP JP2006502990A patent/JP2006517298A/en not_active Ceased
- 2004-02-06 WO PCT/US2004/002009 patent/WO2004072228A2/en active Application Filing
- 2004-02-06 EP EP04708967A patent/EP1590489A4/en not_active Withdrawn
-
2009
- 2009-01-26 US US12/359,854 patent/US7727727B2/en not_active Expired - Fee Related
-
2010
- 2010-05-12 US US12/778,501 patent/US20100286380A1/en not_active Abandoned
Patent Citations (99)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3797202A (en) * | 1971-08-27 | 1974-03-19 | Gen Electric | Microporous/non-porous composite membranes |
US3985649A (en) * | 1974-11-25 | 1976-10-12 | Eddelman Roy T | Ferromagnetic separation process and material |
US3970518A (en) * | 1975-07-01 | 1976-07-20 | General Electric Company | Magnetic separation of biological particles |
US4018886A (en) * | 1975-07-01 | 1977-04-19 | General Electric Company | Diagnostic method and device employing protein-coated magnetic particles |
US4141687A (en) * | 1976-03-12 | 1979-02-27 | Technicon Instruments Corporation | Automatic apparatus and method for the assay of fluid samples |
US4272510A (en) * | 1976-04-26 | 1981-06-09 | Smith Kendall O | Magnetic attraction transfer process for use in solid phase radioimmunoassays and in other assay methods |
US4230685A (en) * | 1979-02-28 | 1980-10-28 | Northwestern University | Method of magnetic separation of cells and the like, and microspheres for use therein |
US4855045A (en) * | 1982-01-14 | 1989-08-08 | Reed Thomas A | Method and apparatus for the separation of organic substances from a suspension or solution |
US4774265A (en) * | 1982-04-23 | 1988-09-27 | Sintef | Process for preparing magnetic polymer particles |
US4672040A (en) * | 1983-05-12 | 1987-06-09 | Advanced Magnetics, Inc. | Magnetic particles for use in separations |
US4695393A (en) * | 1983-05-12 | 1987-09-22 | Advanced Magnetics Inc. | Magnetic particles for use in separations |
US5167811A (en) * | 1984-11-28 | 1992-12-01 | Trustees Of The University Of Pennsylvania | Affinity chromatography using dried calcium alginate-magnetite separation media in a magnetically stabilized fluidized bed |
US5536644A (en) * | 1985-12-20 | 1996-07-16 | Behringwerke Ag | Particle separation method |
US4935147A (en) * | 1985-12-20 | 1990-06-19 | Syntex (U.S.A.) Inc. | Particle separation method |
US5076950A (en) * | 1985-12-20 | 1991-12-31 | Syntex (U.S.A.) Inc. | Magnetic composition for particle separation |
US4900677A (en) * | 1986-09-26 | 1990-02-13 | E. I. Du Pont De Nemours And Company | Process for rapid isolation of high molecular weight DNA |
US4935342A (en) * | 1986-12-01 | 1990-06-19 | Syngene, Inc. | Method of isolating and purifying nucleic acids from biological samples |
US4910148A (en) * | 1987-02-10 | 1990-03-20 | Dynal A. S. | Magnetic separation of magnetized particles from biological fluids |
US5464752A (en) * | 1987-03-13 | 1995-11-07 | Coulter Corporation | Automated analyzer for screening cells or formed bodies for enumeration of populations expressing selected characteristics |
US4946952A (en) * | 1987-04-24 | 1990-08-07 | Hoffmann-La Roche Inc. | Process for isolating nucleic acids |
US5370993A (en) * | 1987-05-19 | 1994-12-06 | Syntex (U.S.A.) Inc. | Reversible agglutination mediators |
US5395688A (en) * | 1987-10-26 | 1995-03-07 | Baxter Diagnostics Inc. | Magnetically responsive fluorescent polymer particles |
US4988618A (en) * | 1987-11-16 | 1991-01-29 | Gene-Trak Systems | Magnetic separation device and methods for use in heterogeneous assays |
US4923978A (en) * | 1987-12-28 | 1990-05-08 | E. I. Du Pont De Nemours & Company | Process for purifying nucleic acids |
US5340749A (en) * | 1988-04-26 | 1994-08-23 | Nippon Telegraph And Telephone Corporation | Method for collecting and preparing specimens for immune reactions |
US5512439A (en) * | 1988-11-21 | 1996-04-30 | Dynal As | Oligonucleotide-linked magnetic particles and uses thereof |
US5543289A (en) * | 1988-12-28 | 1996-08-06 | Miltenyi; Stefan | Methods and materials for improved high gradient magnetic separation of biological materials |
US6020210A (en) * | 1988-12-28 | 2000-02-01 | Miltenvi Biotech Gmbh | Methods and materials for high gradient magnetic separation of biological materials |
US5234809A (en) * | 1989-03-23 | 1993-08-10 | Akzo N.V. | Process for isolating nucleic acid |
US5010183A (en) * | 1989-07-07 | 1991-04-23 | Macfarlane Donald E | Process for purifying DNA and RNA using cationic detergents |
US5336760A (en) * | 1989-09-14 | 1994-08-09 | Baxter International Inc. | Method and useful apparatus for preparing pharmaceutical compositions |
US5084169A (en) * | 1989-09-19 | 1992-01-28 | The University Of Colorado Foundation, Inc. | Stationary magnetically stabilized fluidized bed for protein separation and purification |
US5433847A (en) * | 1989-11-01 | 1995-07-18 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Radial flow chromatography |
US5043070A (en) * | 1989-11-13 | 1991-08-27 | Board Of Control Of Michigan Technological University | Magnetic solvent extraction |
US5681478A (en) * | 1989-12-07 | 1997-10-28 | Diatec Instruments A/S | Method and apparatus for magnetically separating and resuspending super-paramagnetic particles in a solution |
US5279936A (en) * | 1989-12-22 | 1994-01-18 | Syntex (U.S.A.) Inc. | Method of separation employing magnetic particles and second medium |
US5523231A (en) * | 1990-02-13 | 1996-06-04 | Amersham International Plc | Method to isolate macromolecules using magnetically attractable beads which do not specifically bind the macromolecules |
US5681946A (en) * | 1990-02-13 | 1997-10-28 | Amersham International Plc | Precipitating polymers |
US5130423A (en) * | 1990-07-13 | 1992-07-14 | Microprobe Corporation | Non-corrosive compositions and methods useful for the extraction of nucleic acids |
US5129936A (en) * | 1990-07-30 | 1992-07-14 | Wilson Harold W | Processes for the preparation of acid fortified paramagnetic iron sulfate salt compounds for use in the treatment of agricultural soils |
US5652141A (en) * | 1990-10-26 | 1997-07-29 | Oiagen Gmbh | Device and process for isolating nucleic acids from cell suspension |
US5695946A (en) * | 1991-02-14 | 1997-12-09 | Vicam, Lp | Assay method for detecting presence of bacteria |
US5491068A (en) * | 1991-02-14 | 1996-02-13 | Vicam, L.P. | Assay method for detecting the presence of bacteria |
US5422279A (en) * | 1991-03-20 | 1995-06-06 | Reference Diagnostics, Inc. | Lipid fractionation |
US5242833A (en) * | 1991-03-20 | 1993-09-07 | Reference Diagnostics, Inc. | Lipid fractionation |
US5595913A (en) * | 1991-03-20 | 1997-01-21 | Reference Diagnostics, Inc. | Lipid fractionation |
US5646001A (en) * | 1991-03-25 | 1997-07-08 | Immunivest Corporation | Affinity-binding separation and release of one or more selected subset of biological entities from a mixed population thereof |
US5318914A (en) * | 1991-07-22 | 1994-06-07 | Pasteur Sanofi Diagnostics | Process and magnetic device for immunological analysis of a solid phase |
US5684712A (en) * | 1991-10-23 | 1997-11-04 | Cellpro, Inc. | Apparatus and method for cell separation |
US5438128A (en) * | 1992-02-07 | 1995-08-01 | Millipore Corporation | Method for rapid purifiction of nucleic acids using layered ion-exchange membranes |
US5693785A (en) * | 1992-02-13 | 1997-12-02 | Becton, Dickinson And Company | Purification of DNA on Hydroxylated Silicas |
US5474914A (en) * | 1992-07-29 | 1995-12-12 | Chiron Corporation | Method of producing secreted CMV glycoprotein H |
US5897783A (en) * | 1992-09-24 | 1999-04-27 | Amersham International Plc | Magnetic separation method |
US5518890A (en) * | 1992-11-20 | 1996-05-21 | Mccormick & Company, Inc. | Method and apparatus for the quantitation and separation of contaminants from particulate materials |
US6040192A (en) * | 1993-02-01 | 2000-03-21 | Labsystems Oy | Method and means for magnetic particle specific binding assay |
US5386024A (en) * | 1993-02-10 | 1995-01-31 | Gen-Probe Incorporated | Method to prepare nucleic acids from a biological sample using low pH and acid protease |
US5916539A (en) * | 1993-03-02 | 1999-06-29 | Silica Gel Ges. M.B.H. | Superparamagnetic particles, process for producing the same and their use |
US5763203A (en) * | 1993-03-11 | 1998-06-09 | Sinvent As | Immobilization and separation of cells and other particles |
US5647994A (en) * | 1993-06-21 | 1997-07-15 | Labsystems Oy | Method and apparatus for separating magnetic particles from a solution |
US5637687A (en) * | 1993-08-31 | 1997-06-10 | Wiggins; James C. | Methods and compositions for isolating nucleic acids |
US5705062A (en) * | 1993-09-17 | 1998-01-06 | Hoffmann-La Roche Inc. | Analytical device for separating magnetic microparticles from suspensions |
US5773307A (en) * | 1993-09-20 | 1998-06-30 | Bio Merieux | Method and device for determining an analyte in a sample |
US5674997A (en) * | 1993-09-27 | 1997-10-07 | Becton Dickinson And Company | DNA purification on modified siligates |
US5766852A (en) * | 1993-11-16 | 1998-06-16 | Becton, Dickinson And Company | Process for lysing mycobacteria |
US5786208A (en) * | 1993-11-29 | 1998-07-28 | Gen-Probe Incorporated | Method for extracting nucleic acids from a wide range of organisms |
US5541072A (en) * | 1994-04-18 | 1996-07-30 | Immunivest Corporation | Method for magnetic separation featuring magnetic particles in a multi-phase system |
US5834197A (en) * | 1994-05-11 | 1998-11-10 | Genera Technologies Limited | Methods of capturing species from liquids and assay procedures |
US5665554A (en) * | 1994-06-09 | 1997-09-09 | Amersham International Plc | Magnetic bead precipitation method |
US6133037A (en) * | 1994-06-15 | 2000-10-17 | Precision System Science Co., Ltd. | Magnetic material attracting/releasing control method making use of a pipette device and various types of analyzer using the method |
US6096554A (en) * | 1994-06-15 | 2000-08-01 | Precision System Science Co., Ltd. | Magnetic material attracting/releasing control method making use of a pipette device and various types of analyzer using the method |
US6187270B1 (en) * | 1994-07-07 | 2001-02-13 | Roche Diagnostics Gmbh | Device and method for the separation of magnetic microparticles |
US5928958A (en) * | 1994-07-27 | 1999-07-27 | Pilgrimm; Herbert | Superparamagnetic particles, process for their manufacture and usage |
US5625053A (en) * | 1994-08-26 | 1997-04-29 | Board Of Regents For Northern Illinois Univ. | Method of isolating purified plasmid DNA using a nonionic detergent, solution |
US5582988A (en) * | 1994-09-15 | 1996-12-10 | Johnson & Johnson Clinical Diagnostics, Inc. | Methods for capture and selective release of nucleic acids using weakly basic polymer and amplification of same |
US5705628A (en) * | 1994-09-20 | 1998-01-06 | Whitehead Institute For Biomedical Research | DNA purification and isolation using magnetic particles |
US5652348A (en) * | 1994-09-23 | 1997-07-29 | Massey University | Chromatographic resins and methods for using same |
US6020211A (en) * | 1994-10-20 | 2000-02-01 | Labsystems Oy | Separation of magnetic microparticles involving a preconcentration step |
US6231760B1 (en) * | 1995-02-21 | 2001-05-15 | Iqbal W. Siddiqi | Apparatus for mixing and separation employing magnetic particles |
US6033574A (en) * | 1995-02-21 | 2000-03-07 | Siddiqi; Iqbal W. | Method for mixing and separation employing magnetic particles |
US5925573A (en) * | 1995-03-21 | 1999-07-20 | Bio Merieux | Method and device for the determination of an analyte using super paramagnetic reactive particles |
US5922284A (en) * | 1995-05-09 | 1999-07-13 | Fujirebio Inc. | Method and apparatus for agglutination immunoassay |
US5945525A (en) * | 1995-07-07 | 1999-08-31 | Toyo Boseki Kabushiki Kaisha | Method for isolating nucleic acids using silica-coated magnetic particles |
US5955268A (en) * | 1996-04-26 | 1999-09-21 | Abbott Laboratories | Method and reagent for detecting multiple nucleic acid sequences in a test sample |
US6143578A (en) * | 1996-05-10 | 2000-11-07 | Bayer Corporation | Method and apparatus for wash, resuspension, recollection and localization of magnetizable particles in assays using magnetic separation technology |
US5907035A (en) * | 1996-05-23 | 1999-05-25 | Baxter Biotech Technology Sarl | Aqueous two-phase metal affinity partitioning protein purification system |
US5990302A (en) * | 1996-07-12 | 1999-11-23 | Toyo Boseki Kabushiki Kaisha | Method for isolating ribonucleic acid |
US5981235A (en) * | 1996-07-29 | 1999-11-09 | Promega Corporation | Methods for isolating nucleic acids using alkaline protease |
US6210881B1 (en) * | 1996-12-30 | 2001-04-03 | Becton, Dickinson And Company | Method for reducing inhibitors of nucleic acid hybridization |
US6027945A (en) * | 1997-01-21 | 2000-02-22 | Promega Corporation | Methods of isolating biological target materials using silica magnetic particles |
US5998224A (en) * | 1997-05-16 | 1999-12-07 | Abbott Laboratories | Magnetically assisted binding assays utilizing a magnetically responsive reagent |
US6008002A (en) * | 1997-09-29 | 1999-12-28 | Bodey; Bela | Immunomagnetic detection and isolation of cancer cells |
US20010018513A1 (en) * | 1997-12-06 | 2001-08-30 | Baker Matthew John | Isolation of nucleic acids |
US6099738A (en) * | 1997-12-17 | 2000-08-08 | Micromag Corporation | Method and system for removing solutes from a fluid using magnetically conditioned coagulation |
US6146511A (en) * | 1998-01-30 | 2000-11-14 | The Perkin-Elmer Corporation | Electrophoretic nucleic acid purification method |
US6355792B1 (en) * | 1998-02-04 | 2002-03-12 | Merck Patent Gesellschaft | Method for isolating and purifying nucleic acids |
US6265164B1 (en) * | 1998-03-26 | 2001-07-24 | Biochain Institute, Inc. | Compositions and methods for directly and rapidly analyzing the biochemical components of microorganisms |
US6024881A (en) * | 1998-08-11 | 2000-02-15 | Just; Gerard A. | Magnetic absorption treatment of fluid phases |
US5973138A (en) * | 1998-10-30 | 1999-10-26 | Becton Dickinson And Company | Method for purification and manipulation of nucleic acids using paramagnetic particles |
US6294342B1 (en) * | 1999-09-29 | 2001-09-25 | Abbott Laboratories | Magnetically assisted binding assays utilizing a magnetically responsive reagent |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012083198A2 (en) * | 2010-12-17 | 2012-06-21 | University Of Utah Research Foundation | Methods and compositions for purifying dna |
WO2012083198A3 (en) * | 2010-12-17 | 2014-04-10 | University Of Utah Research Foundation | Methods and compositions for purifying dna |
Also Published As
Publication number | Publication date |
---|---|
JP2006517298A (en) | 2006-07-20 |
US7727727B2 (en) | 2010-06-01 |
WO2004072228A3 (en) | 2005-08-25 |
EP1590489A4 (en) | 2006-09-27 |
US20090130736A1 (en) | 2009-05-21 |
CA2515040A1 (en) | 2004-08-26 |
US7601491B2 (en) | 2009-10-13 |
EP1590489A2 (en) | 2005-11-02 |
US20040157218A1 (en) | 2004-08-12 |
WO2004072228A2 (en) | 2004-08-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7727727B2 (en) | Pretreatment method for extraction of nucleic acid from biological samples and kits therefor | |
US20070031880A1 (en) | Chemical treatment of biological samples for nucleic acid extraction and kits therefor | |
JP5354894B2 (en) | Nucleic acid isolation using polidocanols and derivatives | |
CN109072234B (en) | Protein-based sample collection matrices and devices | |
KR101066179B1 (en) | Method for extraction of nucleic acid from biological material | |
EP0626456B1 (en) | Method for processing mycobacteria-containing sputum samples | |
CA2153215A1 (en) | Treatment of paraffin embedded tissue for gene analysis | |
JP2012157366A (en) | Eluting reagent, method and kit for isolating dna | |
JP5300112B2 (en) | Compositions and methods for using a lysis matrix for isolating DNA | |
EP2115123A2 (en) | Selective lysis of sperm cells | |
EP2426222A1 (en) | Generic buffer for amplification | |
JP2000300262A (en) | Extraction of nucleic acid using particule carrier | |
US20170191054A1 (en) | Methods for extraction and purification of components of biological samples | |
JP4616990B2 (en) | Method for isolating, amplifying and characterizing DNA | |
JP4214255B2 (en) | Improved nucleic acid extraction method using particle carrier | |
CN113930418A (en) | Nucleic acid releasing agent and method for releasing nucleic acid | |
NO324041B1 (en) | Method for extracting DNA, as well as method for detecting a DNA-containing microorganism in serum or plasma. | |
JP2001139593A (en) | Method for improved extraction of nucleic acid by using particle carrier | |
JP2000245456A (en) | Evaluation of recovering amount of nucleic acid |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |